



(11) **EP 1 187 918 B9**

(12) **CORRECTED NEW EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B2)
Corrections, see
Claims EN 1, 2, 8

(51) Int Cl.:
C12N 15/12 (2006.01) **C07K 14/71** (2006.01)
G01N 33/68 (2006.01) **C07K 19/00** (2006.01)
C07K 16/28 (2006.01) **A61K 38/17** (2006.01)
A61K 39/395 (2006.01)

(48) Corrigendum issued on:
19.08.2009 Bulletin 2009/34

(86) International application number:
PCT/US2000/015706

(45) Date of publication and mention
of the opposition decision:
14.01.2009 Bulletin 2009/03

(87) International publication number:
WO 2000/075323 (14.12.2000 Gazette 2000/50)

(45) Mention of the grant of the patent:
26.04.2006 Bulletin 2006/17

(21) Application number: **00938207.8**

(22) Date of filing: **07.06.2000**

(54) **TEK ANTAGONISTS**
TEK-ANTAGONISTEN
ANTAGONISTES TEK

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

(30) Priority: **07.06.1999 US 137889 P**

(43) Date of publication of application:
20.03.2002 Bulletin 2002/12

(73) Proprietor: **Immunex Corporation**
Thousand Oaks, CA 91320-1799 (US)

(72) Inventors:
• **CERRETTI, Douglas, P.**
Seattle, WA 98133 (US)

• **BORGES, Luis, G.**
Seattle, WA 98107 (US)
• **FANSLOW, William, C., III**
Normandy Park, WA 98166 (US)

(74) Representative: **Cornish, Kristina Victoria Joy et al**
Kilburn & Strode LLP
20 Red Lion Street
London
WC1R 4PJ (GB)

(56) References cited:
WO-A-94/00469 **WO-A-95/13387**
WO-A-95/21866 **WO-A-96/11269**
WO-A-96/31598

EP 1 187 918 B9

Description**FIELD OF THE INVENTION**

[0001] The present invention relates to Tek antagonists and to the use of Tek antagonists to inhibit angiogenesis or other Tek-mediated responses in a mammal.

BACKGROUND OF THE INVENTION**A. Angiogenesis**

[0002] Angiogenesis, the generation of new blood vessels, is a spatially and temporally regulated process in which endothelial cells proliferate, migrate, and assemble into tubes, in response to endogenous positive and negative regulatory molecules. Angiogenesis plays important roles in both normal and pathological physiology.

[0003] Under normal physiological conditions, angiogenesis is involved in fetal and embryonic development, wound healing, organ regeneration, and female reproductive remodeling processes including formation of the endometrium, corpus luteum, and placenta. Angiogenesis is stringently regulated under normal conditions, especially in adult animals, and perturbation of the regulatory controls can lead to pathological angiogenesis.

[0004] Pathological angiogenesis has been implicated in the manifestation and/or progression of inflammatory diseases, certain eye disorders, and cancer. In particular, several lines of evidence support the concept that angiogenesis is essential for the growth and persistence of solid tumors and their metastases (see, e.g., Folkman, N. Engl. J. Med. 285:1182, 1971; Folkman et al., Nature 339:58, 1989; Kim et al., Nature 362:841, 1993; Hori et al., Cancer Res., 51: 6180, 1991). Angiogenesis inhibitors are therefore being tested for the prevention (e.g., treatment of premalignant conditions), intervention (e.g., treatment of small tumors), and regression (e.g., treatment of large tumors) of cancers (see, e.g., Bergers et al., Science 284:808, 1999).

[0005] Although several anti-angiogenic agents are presently under development and testing as therapeutics, there is a need for additional methods of inhibiting angiogenesis for the prevention, abrogation, and mitigation of disease processes that are dependent on pathological angiogenesis.

B. Tek Polypeptides

[0006] The receptor tyrosine kinases (RTKs) are a large and evolutionarily conserved family of proteins involved in the transduction of extracellular signals to the cytoplasm. Among the RTKs believed to be involved in vascular morphogenesis and maintenance are the vascular endothelial growth factor (VEGF) receptor and Tek (see Hanahan. Science 277:48, 1997).

[0007] Tek, which has also been called Tie2 and ork, is an RTK that is predominantly expressed in vascular endothelium. The molecular cloning of human Tek (ork) has been described by Ziegler, U.S. Patent No. 5,447,860. Four Tek ligands, angiopoietin-1, angiopoietin-2, angiopoietin-3, and angiopoietin-4 (Ang1, Ang2, Ang3, and Ang4), have been described (Davis et al., Cell 87:1161, 1996; Maisonpierre et al., Science 277:55, 1997; Valenzuela et al., Proc. Natl. Acad. Sci. USA 96:1904, 1999). These ligands have distinct expression patterns and activities with respect to Tek. "Tie ligand homologues" designated NL 1, NL5, NL8, and NL4 are described in U.S. Patent No. 6,057,435.

[0008] Tek knockout mice have defects in vascular development, and die during embryogenesis (see Dumont, Genes Dev. 8:1897, 1994; Sato, Nature 376:70, 1995), suggesting that Tek plays a role in the development of embryonic vasculature.

[0009] Peters et al. have described a soluble Tek (Tie2) inhibitor designated ExTek.6His, consisting of the entire extracellular portion of murine Tek fused to a six-histidine tag (J. Clin. Invest. 199(8):2072, 1997; WO 98/18914). ExTek.6His inhibited growth and tumor vascularization in a rat cutaneous window chamber model, and blocked angiogenesis stimulated by tumor cell conditioned media in a rat corneal micropocket assay. Peters et al. have also described a replication-defective adenoviral vector designated AdExTek, which expresses the murine Tek extracellular domain (Proc. Natl. Acad. Sci. USA 95:8829, 1998; WO 98/18914). AdExTek inhibited the growth and metastasis of a murine mammary carcinoma and a murine melanoma.

[0010] While ExTek.6His and AdExTek may prove useful as anti-angiogenic agents, there is a need for additional and improved Tek antagonists and additional and improved methods of inhibiting angiogenesis or other Tek-mediated responses using Tek antagonists.

SUMMARY OF THE INVENTION

[0011] The present invention provides Tek antagonists and the use of Tek antagonists to inhibit angiogenesis or other

Tek-mediated responses in a mammal in need of such treatment. The invention is based in part on the unexpected discovery that fragments of the Tek extracellular domain, lacking all or part of the region containing fibronectin type III (FNIII) motifs, can have a higher binding affinity for Tek ligands than polypeptides comprising full length Tek extracellular domain.

[0012] In a first aspect, the present invention provides a polypeptide comprising the Tek extracellular domain shown as residues 19-745 of SEQ ID NO:1 wherein the polypeptide lacks residues 473-745 of SEQ ID NO:1 containing fibronectin type III (FNIII) motifs and wherein the polypeptide has a higher binding affinity for angiopoietin-1 or angiopoietin-2 or angiopoietin-4 than does a polypeptide comprising full length Tek extracellular domain.

[0013] The Tek extracellular domain may be selected from the group consisting of:

- (a) residues 23-472 of SEQ ID NO:2;
- (b) variants that are at least 95% identical to (a);
- (c) variants that are at least 98% identical to (a);
- (d) variants that are at least 99% identical to (a); and
- (e) residues 19-472 of SEQ ID NO:2

[0014] The polypeptide may consist of residues 19-704 or 23-704 of SEQ ID NO:2.

[0015] The invention also encompasses nucleic acids encoding polypeptides according to the invention, and polypeptides produced by expressing such a nucleic acid in a recombinant host cell under conditions that permit expression of the polypeptide.

[0016] In some preferred embodiments, the Tek antagonist is a soluble Tek multimer of the polypeptide of the invention, preferably a dimer or trimer, and most preferably comprising an Fc polypeptide or a leucine zipper. The Tek is preferably human Tek.

[0017] The invention also provides the use of a polypeptide of the invention or a soluble Tek multimer of the invention in the manufacture of a medicament for use in inhibiting angiogenesis. In some preferred embodiments the Tek is human Tek and the medicament further comprises a pharmaceutically acceptable carrier.

[0018] The medicament may be used in the treatment of a disease or condition mediated by angiogenesis, more preferably a solid tumor or a disease or condition characterized by ocular neovascularization.

[0019] In some embodiments the medicament further comprises a second chemotherapeutic agent and/or is suitable for use in combination with radiation. The second chemotherapeutic agent may be selected from the group consisting of alkylating agents, antimetabolites, vinca alkaloids and other plant-derived chemotherapeutics, nitrosoureas, antitumor antibiotics, antitumor enzymes; topoisomerase inhibitors, platinum analogs, adrenocortical suppressants, hormones, hormone agonists, hormone antagonists, antibodies, immunotherapeutics, blood cell factors, radiotherapeutics, and biological response modifiers, and more preferably selected from the group consisting of cisplatin, cyclophosphamide, mechlorethamine, melphalan, bleomycin, carboplatin, fluorouracil, 5-fluorodeoxyuridine, methotrexate, taxol, asparaginase, vincristine, and vinblastine, lymphokines and cytokines such as interleukins, interferons (including alpha, beta, or delta), and TNF, chlorambucil, busulfan, carmustine, lomustine, semustine, streptozocin, dacarbazine, cytarabine, mercaptopurine, thioguanine, vindesine, etoposide, teniposide, dactinomycin, daunorubicin, doxorubicin, bleomycin, plitacimycin, mitomycin, L-asparaginase, hydroxyurea, methylhydrazine, mitotane, tamoxifen, and fluoxymesterone, Flt3 ligand, CD40 ligand, interleukin-2, interleukin-12, 4-1BB ligand, anti-4-1BB antibodies, TNF antagonists and TNF receptor antagonists, TRAIL, CD 148 agonists, VEGF antagonists, and VEGF receptor antagonists.

[0020] These and other aspects of the present invention will become evident upon reference to the following drawings and detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

[0021]

Figure 1 shows inhibition by Tek472/Fc of endothelial cell migration in a wound closure assay.

Figure 2 shows inhibition by Tek472/Fc of angiogenesis in a corneal pocket assay.

Figure 3 shows tumor growth after treatment with Tek472/Fc, Flt3L, and combinations of Tek472/Fc and Flt3L, in mice with 87 fibrosarcoma tumors.

Figure 4 shows tumor growth after treatment with Tek472/Fc, Flt3L, and combinations of Tek472/Fc and Flt3L in mice with B10.2 fibrosarcoma tumors.

Figure 5 shows the binding of Tek472/Fc and Tek745/Fc to human angiopoietin-2.

DETAILED DESCRIPTION OF THE INVENTION

[0022] The present invention is directed to Tek antagonists and the use of Tek antagonists to inhibit angiogenesis or other Tek-mediated responses in a mammal. Tek antagonists are compounds or compositions that interfere with one or more biological activities of Tek, including ligand binding and signal transduction, and may be characterized using methods such as those exemplified below. Tek antagonists include fragments of the Tek extracellular domain and soluble Tek multimers. The molecular cloning of a cDNA encoding human Tek (ork. Tie2) is described in U.S. Patent No. 5,447,860.

A. Abbreviations and Terminology Used in the Specification

[0023] "4-1BB" and "4-1BB ligand" (4-1BB-L) are polypeptides described, inter alia, in U.S. Patent No. 5,674,704, including soluble forms thereof.

[0024] "bFGF" is basic fibroblast growth factor.

[0025] "BSA" is bovine serum albumin.

[0026] "CD40 ligand" (CD40L) is a polypeptide described, inter alia, in U.S. Patent No. 5,716,805, including soluble forms thereof.

[0027] "CHO" is a Chinese hamster ovary cell line.

[0028] "DMEM" is Dulbecco's Modified eagle Medium, a commercially available cell culture medium.

[0029] "ELISA" is Enzyme-Linked Immunosorbent Assay.

[0030] "Flt3L" is Flt3 ligand, a polypeptide described, inter alia, in U.S. Patent No. 5,554,512, including soluble forms thereof.

[0031] "HMVEC-d" are primary dermal human microvascular endothelial cells.

[0032] "HRMEC" are primary human renal microvascular endothelial cells.

[0033] "HUVEC" is a line of human umbilical vein endothelial cells.

[0034] "mAb" is a monoclonal antibody.

[0035] "MSA" is mouse serum albumin.

[0036] "PBS" is phosphate buffered saline.

[0037] "PE" is phycoerythrin.

[0038] "PMA" is phorbol 12-myristate-13-acetate.

[0039] "RTKs" are receptor tyrosine kinases.

[0040] "TNF" is a tumor necrosis factor. "TNFR/Fc" is a TNF receptor-Fc fusion polypeptide.

[0041] "TRAIL" is TNF-related apoptosis-inducing ligand, a type II transmembrane polypeptide in the TNF family described, inter alia, in U.S. Patent No. 5,763,223. including soluble forms thereof.

[0042] "VEGF" is vascular endothelial growth factor.

B. Soluble Tek Polypeptides .

[0043] In one aspect of the present invention, a soluble Tek polypeptide is used as a Tek antagonist to inhibit angiogenesis or to inhibit the binding of a Tek ligand to Tek.

[0044] Soluble polypeptides are capable of being secreted from the cells in which they are expressed. The use of soluble forms of polypeptides is advantageous for certain applications. Purification of the polypeptides from recombinant host cells is facilitated since the polypeptides are secreted, and soluble proteins are generally suited for parenteral administration. A secreted soluble polypeptide may be identified (and distinguished from its non-soluble membrane-bound counterparts) by separating intact cells which express the desired polypeptide from the culture medium, e.g., by centrifugation, and assaying the medium (supernatant) for the presence of the desired polypeptide. The presence of the desired polypeptide in the medium indicates that the polypeptide was secreted from the cells and thus is a soluble form of the polypeptide. Soluble polypeptides may be prepared by any of a number of conventional techniques. A DNA sequence encoding a desired soluble polypeptide may be subcloned into an expression vector for production of the polypeptide, or the desired encoding DNA fragment may be chemically synthesized.

[0045] Soluble Tek polypeptides comprise all or part of the Tek extracellular domain, but generally lack the transmembrane domain that would cause retention of the polypeptide at the cell surface. Soluble polypeptides may include part of the transmembrane domain or all or part of the cytoplasmic domain as long as the polypeptide is secreted from the cell in which it is produced. Soluble Tek polypeptides advantageously comprise a native or heterologous signal peptide when initially synthesized, to promote secretion from the cell, but the signal sequence is cleaved upon secretion. The term "Tek extracellular domain" is intended to encompass all or part of the native Tek extracellular domain, as well as related forms including but not limited to: (a) fragments, (b) variants, (c) derivatives, and (d) fusion polypeptides. The ability of these related forms to inhibit angiogenesis or other Tek-mediated responses may be determined in vitro or in

vivo, using methods such as those exemplified below or using other assays known in the art.

[0046] Examples of soluble Tek polypeptides are provided the examples below. As described in the examples, the Inventors unexpectedly discovered that certain fragments of the Tek extracellular domain bind Tek ligands better than the full length Tek extracellular domain, that these fragments can therefore be used as antagonists to block the binding of Tek ligands to Tek (for example, the Tek found on a cell surface), and that antibodies to these fragments can also be used as antagonists to block the binding of Tek ligands to Tek. In some embodiments of the present invention a multimeric form of a soluble Tek polypeptide ("soluble Tek multimer") is used as an antagonist to block the binding of Tek ligands to Tek, to inhibit angiogenesis or other Tek-mediated responses.

C- Soluble Tek Multimers

[0047] Soluble Tek multimers are covalently-linked or non-covalently-linked multimers, including dimers, trimers, or higher multimers. Multimers may be linked by disulfide bonds formed between cysteine residues on different soluble Tek polypeptides. One embodiment of the invention is directed to multimers comprising multiple soluble Tek polypeptides joined via covalent or non-covalent interactions between peptide moieties fused to the soluble Tek polypeptides. Such peptides may be peptide linkers (spacers), or peptides that have the property of promoting multimerization. Leucine zippers and certain polypeptides derived from antibodies are among the peptides that can promote multimerization of soluble Tek polypeptides attached thereto, as described in more detail below. In particular embodiments, the multimers comprise from two to four soluble Tek polypeptides.

[0048] In some embodiments, a soluble Tek multimer is prepared using polypeptides derived from immunoglobulins. Preparation of fusion proteins comprising certain heterologous polypeptides fused to various portions of antibody-derived polypeptides (including the Fc domain) has been described, e.g., by Ashkenazi et al. (Proc. Natl. Acad. Sci. USA 88: 10535, 1991); Byrn et al. (Nature 344:677, 1990); and Hollenbaugh and Aruffo ("Construction of Immunoglobulin Fusion Proteins", in Current Protocols in Immunology, Suppl. 4, pages 10. 19.1-10.19.11. 1992).

[0049] One preferred embodiment of the present invention is directed to a Tek/Fc dimer comprising two fusion proteins created by fusing soluble Tek to an Fc polypeptide. A gene fusion encoding the Tek/Fc fusion protein is inserted into an appropriate expression vector. Tek/Fc fusion proteins are expressed in host cells transformed with the recombinant expression vector, and allowed to assemble much like antibody molecules, whereupon interchain disulfide bonds form between the Fc moieties to yield divalent soluble Tek. The term "Fc polypeptide" as used herein includes native and mutein forms of polypeptides derived from the Fc region of an antibody. Truncated forms of such polypeptides containing the hinge region that promotes dimerization are also included.

[0050] One suitable Fc polypeptide, described in PCT application WO 93/10151, is a single chain polypeptide extending from the N-terminal hinge region to the native C-terminus of the Fc region of a human IgG1 antibody. Another useful Fc polypeptide is the Fc mutein described in U.S. Patent 5,457,035 and by Baum et al., EMBO J. 13:3992, 1994. The amino acid sequence of this mutein is identical to that of the native Fc sequence presented in WO 93/10151, except that amino acid 19 has been changed from Leu to Ala, amino acid 20 has been changed from Leu to Glu, and amino acid 22 has been changed from Gly to Ala. The mutein exhibits reduced affinity for Fc receptors. Fusion polypeptides comprising Fc moieties, and multimers formed therefrom, offer an advantage of facile purification by affinity chromatography over Protein A or Protein G columns, and Fc fusion polypeptides may provide a longer in vivo half life, which is useful in therapeutic applications, than unmodified polypeptides.

[0051] In other embodiments, a soluble Tek polypeptide may be substituted for the variable portion of an antibody heavy or light chain. If fusion proteins are made with both heavy and light chains of an antibody, it is possible to form a soluble Tek multimer with as many as four soluble Tek polypeptides.

[0052] Alternatively, the soluble Tek multimer is a fusion protein comprising multiple soluble Tek polypeptides, with or without peptide linkers (spacers), or peptides that have the property of promoting multimerization. Among the suitable peptide linkers are those described in U.S. Patents 4,751,180, 4,935,233, and 5,073,627. A DNA sequence encoding a desired peptide linker may be inserted between, and in the same reading frame as, the DNA sequences encoding Tek, using conventional techniques known in the art. For example, a chemically synthesized oligonucleotide encoding the linker may be ligated between sequences encoding soluble Tek. In particular embodiments, a fusion protein comprises from two to four soluble Tek polypeptides, separated by peptide linkers.

[0053] Another method for preparing soluble Tek multimers involves use of a leucine zipper domain. Leucine zipper domains are peptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, 1988), and have since been found in a variety of different proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins are described in PCT application WO 94/10308, and the leucine zipper derived from lung surfactant protein D (SPD) described in Hoppe et al. FEBS Lett. 344:191, 1994. The use of a modified leucine zipper that allows for stable trimerization of a heterologous protein fused thereto is described in Fanslow et al., Semin. Immunol. 6:267, 1994. Recombinant fusion

proteins comprising a soluble Tek polypeptide fused to a leucine zipper peptide are expressed in suitable host cells, and the soluble Tek multimer that forms is recovered from the culture supernatant.

[0054] For some applications, the soluble Tek multimers of the present invention are believed to provide certain advantages over the use of monomeric forms, including the advantage of mimicking the natural interaction between a ligand and a receptor tyrosine kinase (RTK). In general, a dimer ligand will bind and cause dimerization of the RTK (van der Geer et al., Ann. Rev. Cell Biol. 10:251, 1994). This high affinity binding causes transphosphorylation of the RTK and the beginning of the signal transduction process. The binding of a soluble Tek multimer may occur at higher affinity than will a soluble Tek monomer. Fc fusion polypeptides offer an additional advantage in that this form typically exhibits an increased in vivo half life as compared to an unmodified polypeptide.

[0055] The present invention encompasses the use of various forms of soluble Tek multimers that retain the ability to inhibit angiogenesis or other Tek-mediated responses. The term "soluble Tek multimer" is intended to encompass multimers containing all or part of the native Tek extracellular domain, as well as related forms including, but not limited to, multimers of: (a) fragments, (b) variants, (c) derivatives, and (d) fusion polypeptides of soluble Tek. The ability of these related forms to inhibit angiogenesis or other Tek-mediated responses may be determined in vitro or in vivo, using methods such as those exemplified in the examples or using other assays known in the art.

[0056] Among the soluble Tek polypeptides and soluble Tek multimers useful in practicing the present invention are Tek variants that retain the ability to bind ligand and/or inhibit angiogenesis or other Tek-mediated responses. Such Tek variants include polypeptides that are substantially homologous to native Tek, but which have an amino acid sequence different from that of a native Tek because of one or more deletions, insertions or substitutions. Particular embodiments include, but are not limited to, Tek polypeptides that comprise from one to ten deletions, insertions or substitutions of amino acid residues, when compared to a native Tek sequence. Included as variants of Tek polypeptides are those variants that are naturally occurring, such as allelic forms and alternatively spliced forms, as well as variants that have been constructed by modifying the amino acid sequence of a Tek polypeptide or the nucleotide sequence of a nucleic acid encoding a Tek polypeptide.

[0057] Generally, substitutions for one or more amino acids present in the native polypeptide should be made conservatively. Examples of conservative substitutions include substitution of amino acids outside of the active domain(s), and substitution of amino acids that do not alter the secondary and/or tertiary structure of Tek. Additional examples include substituting one aliphatic residue for another, such as Ile, Val, Leu, or Ala for one another, or substitutions of one polar residue for another, such as between Lys and Arg; Glu and Asp; or Gln and Asn, or substitutions of one aromatic residue for another, such as Phe, Trp, or Tyr for one another. Other such conservative substitutions, for example, substitutions of entire regions having similar hydrophobicity characteristics, are known in the art.

[0058] The native sequence of the full length Tek extracellular domain is set forth as residues 23-745 of SEQ ID NO: 1. Percent identity, in the case of both polypeptides and nucleic acids, may be determined by visual inspection. Percent identity may also be determined using the alignment method of Needleman and Wunsch (J. Mol. Biol. 48:443, 1970) as revised by Smith and Waterman (Adv. Appl. Math 2:482, 1981). Preferably, percent identity is determined by using a computer program, for example, the GAP computer program version 10.x available from the Genetics Computer Group (GCG; Madison, WI, see also Devereux et al., Nucl. Acids Res. 12:387, 1984). The preferred default parameters for the GAP program include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) for nucleotides, and the weighted comparison matrix of Gribskov and Burgess, Nucl. Acids Res. 14:6745, 1986, as described by Schwartz and Dayhoff, eds., Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, pp. 353-358, 1979 for amino acids: (2) a penalty of 30 (amino acids) or 50 (nucleotides) for each gap and an additional 1 (amino acids) or 3 (nucleotides) penalty for each symbol in each gap; (3) no penalty for end gaps; and (4) no maximum penalty for long gaps. Other programs used by one skilled in the art of sequence comparison may also be used. For fragments of Tek, the percent identity is calculated based on that portion of Tek that is present in the fragment.

[0059] The present invention further encompasses the use of soluble Tek polypeptides with or without associated native-pattern glycosylation. Tek expressed in yeast or mammalian expression systems (e.g., COS-1 or COS-7 cells) may be similar to or significantly different from a native Tek polypeptide in molecular weight and glycosylation pattern, depending upon the choice of expression system. Expression of Tek polypeptides in bacterial expression systems, such as *E. coli*, provides non-glycosylated molecules. Different host cells may also process polypeptides differentially, resulting in heterogeneous mixtures of polypeptides with variable N- or C-termini.

[0060] The primary amino acid structure of soluble Tek polypeptides may be modified to create derivatives by forming covalent or aggregative conjugates with other chemical moieties, such as glycosyl groups, lipids, phosphate, acetyl groups and the like. Covalent derivatives of Tek may be prepared by linking particular functional groups to Tek amino acid side chains or at the N-terminus or C-terminus of a Tek polypeptide.

[0061] Fusion polypeptides of soluble Tek that are useful in practicing the invention also include covalent or aggregative conjugates of a Tek polypeptide with other polypeptides added to provide novel polyfunctional entities.

D. Recombinant Production of Tek Polypeptides

[0062] Tek polypeptides, including soluble Tek polypeptides, fragments, and fusion polypeptides, used in the present invention may be prepared using a recombinant expression system. Host cells transformed with a recombinant expression vector ("recombinant host cells") encoding the Tek polypeptide are cultured under conditions that promote expression of Tek and the Tek is recovered. Tek polypeptides can also be produced in transgenic plants or animals, or by chemical synthesis.

[0063] The invention encompasses nucleic acid molecules encoding the Tek polypeptides used in the invention, including nucleic acids that encode residues 23-472 of SEQ ID NO:2. The nucleic acid may further encode a signal peptide sequence and may encode SEQ ID NO:2.

[0064] Due to degeneracy of the genetic code, there can be considerable variation in nucleotide sequences encoding the same amino acid sequence. Also disclosed are Nucleic acid sequences capable of hybridizing under moderately stringent conditions (e.g., prewashing solution of 5 X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0) and hybridization conditions of 50°C, 5 X SSC, overnight) to the DNA sequences encoding Tek. The skilled artisan can determine additional combinations of salt and temperature that constitute moderate hybridization stringency (see also, Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989; Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1982; and Ausubel, Current Protocols in Molecular Biology, Wiley and Sons, 1989 and later versions Conditions of higher stringency include higher temperatures for hybridization and post-hybridization washes, and/or lower salt concentration. Percent identity of nucleic acids may be determined using the methods described above for polypeptides. i.e., by methods including visual inspection and the use of computer programs such as GAP.

[0065] Any suitable expression system may be employed for the production of recombinant Tek. Recombinant expression vectors include DNA encoding a Tek polypeptide operably linked to suitable transcriptional and translational regulatory nucleotide sequences, such as those derived from a mammalian, microbial, viral, or insect gene. Nucleotide sequences are operably linked when the regulatory sequence functionally relates to the Tek DNA sequence. Thus, a promoter nucleotide sequence is operably linked to a Tek DNA sequence if the promoter nucleotide sequence controls the transcription of the Tek DNA sequence. Examples of regulatory sequences include transcriptional promoters, operators, or enhancers, an mRNA ribosomal binding site, and appropriate sequences which control transcription and translation initiation and termination. A sequence encoding an appropriate signal peptide (native or heterologous) can be incorporated into expression vectors. A DNA sequence for a signal peptide (referred to by a variety of names including secretory leader, leader peptide, or leader) may be fused in frame to the Tek sequence so that the Tek polypeptide is initially translated as a fusion protein comprising the signal peptide. A signal peptide that is functional in the intended host cells promotes extracellular secretion of the Tek polypeptide. The signal peptide is cleaved from the Tek polypeptide upon secretion of Tek from the cell.

[0066] Suitable host cells for expression of Tek polypeptides include prokaryotes, yeast and higher eukaryotic cells, including insect and mammalian cells. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, insect, and mammalian cellular hosts are described, for example, in Pouwels et al. Cloning Vectors: A Laboratory Manual, Elsevier, New York, 1985.

[0067] Prokaryotes include gram negative or gram positive organisms, for example, *E. coli* or *Bacilli*. Suitable prokaryotic host cells for transformation include, for example, *E. coli*, *Bacillus subtilis*, *Salmonella typhimurium*, and various other species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*. In a prokaryotic host cell, such as *E. coli*, Tek polypeptides may include an N-terminal methionine residue to facilitate expression of the recombinant polypeptide in the prokaryotic host cell. The N-terminal Met may be cleaved from the expressed recombinant polypeptide.

[0068] Expression vectors for use in prokaryotic host cells generally comprise one or more phenotypic selectable marker gene(s). A phenotypic selectable marker gene is, for example, a gene encoding a protein that confers antibiotic resistance or that supplies an autotrophic requirement. Examples of useful expression vectors for prokaryotic host cells include those derived from commercially available plasmids such as the cloning vector pBR322 (ATCC 37017). pBR322 contains genes for ampicillin and tetracycline resistance and thus provides simple means for identifying transformed cells. An appropriate promoter and a Tek DNA sequence are inserted into the pBR322 vector. Other commercially available vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and pGEM 1 (Promega Biotec, Madison, WI, USA).

[0069] Promoter sequences commonly used for recombinant prokaryotic host cell expression vectors include β -lactamase (penicillinase), lactose promoter system (Chang et al., Nature 275:615, 1978; Goeddel et al., Nature 281:544, 1979), tryptophan (trp) promoter system (Goeddel et al., Nucl. Acids Res. 8:4057, 1980; EP-A-36776) and tac promoter (Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, p. 412, 1982). A particularly useful prokaryotic host cell expression system employs a phage λ P_L promoter and a cl857ts thermolabile repressor sequence. Plasmid vectors available from the American Type Culture Collection which incorporate derivatives of the λ P_L promoter include plasmid pHUB2 (resident in *E. coli* strain JMB9, ATCC 37092) and pPLc28 (resident in *E. coli* RR1, ATCC 53082).

[0070] Tek polypeptides may also be expressed in yeast host cells, preferably from the *Saccharomyces* genus (e.g.,

S. cerevisiae). Other genera of yeast, such as *Pichia* or *Kluyveromyces*, may also be employed. Yeast vectors will often contain an origin of replication sequence from a 2 μ yeast plasmid, an autonomously replicating sequence (ARS), a promoter region, sequences for polyadenylation, sequences for transcription termination, and a selectable marker gene. Suitable promoter sequences for yeast vectors include, among others, promoters for metallothionein, 3-phosphoglycerate kinase (Hitzeman et al., J. Biol. Chem. 255:2073, 1980) or other glycolytic enzymes (Hess et al., J. Adv. Enzyme Reg. 7:149, 1968; Holland et al., Biochem. 17:4900, 1978), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phospho-glucose isomerase, and glucokinase. Other suitable vectors and promoters for use in yeast expression are further described in Hitzeman, EPA-73,657. Another alternative is the glucose-repressible ADH2 promoter described by Russell et al. (J. Biol. Chem. 258:2674, 1982) and Beier et al. (Nature 300:724, 1982). Shuttle vectors replicable in both yeast and *E. coli* may be constructed by inserting DNA sequences from pBR322 for selection and replication in *E. coli* (Amp^r gene and origin of replication) into the above-described yeast vectors.

[0071] The yeast α -factor leader sequence may be employed to direct secretion of recombinant polypeptides. The α -factor leader sequence is often inserted between the promoter sequence and the structural gene sequence. See, e.g., Kurjan et al., Cell 30:933, 1982; Bitter et al., Proc. Natl. Acad. Sci. USA 81:5330, 1984. Other leader sequences suitable for facilitating secretion of recombinant polypeptides from yeast hosts are known to those of skill in the art. A leader sequence may be modified near its 3' end to contain one or more restriction sites. This will facilitate fusion of the leader sequence to the structural gene.

[0072] Yeast transformation protocols are known to those of skill in the art. One such protocol is described by Hinnen et al., Proc. Natl. Acad. Sci. USA 75:1929, 1978. The Hinnen et al. protocol selects for Trp⁺ transformants in a selective medium, wherein the selective medium consists of 0.67% yeast nitrogen base. 0.5% casamino acids, 2% glucose, 10 μ g/ml adenine and 20 μ g/ml uracil.

[0073] Yeast host cells transformed by vectors containing an ADH2 promoter sequence may be grown for inducing expression in a "rich" medium. An example of a rich medium is one consisting of 1% yeast extract, 2% peptone, and 1% glucose supplemented with 80 μ g/ml adenine and 80 μ g/ml uracil. Derepression of the ADH2 promoter occurs when glucose is exhausted from the medium.

[0074] Insect host cell culture systems also may be employed to express recombinant Tek polypeptides, including soluble Tek polypeptides. Baculovirus systems for production of heterologous polypeptides in insect cells are reviewed by Luckow and Summers. Bio/Technology 6:47, 1988.

[0075] Mammalian cells are particularly preferred for use as host cells. Examples of suitable mammalian host cell lines include the COS-7 line of monkey kidney cells (ATCC CRL 1651) (Gluzman et al., Cell 23:175, 1981), L cells, C127 cells, 3T3 cells (ATCC CCL 163), Chinese hamster ovary (CHO) cells, HeLa cells, and BHK (ATCC CRL 10) cell lines, and the CV1/EBNA cell line derived from the African green monkey kidney cell line CV1 (ATCC CCL 70) as described by McMahan et al. (EMBO J. 10:2821, 1991). For the production of therapeutic polypeptides it is particularly advantageous to use a mammalian host cell line which has been adapted to grow in media that does not contain animal proteins.

[0076] Established methods for introducing DNA into mammalian cells have been described (Kaufman, R.J., Large Scale Mammalian Cell Culture, 1990, pp. 15-69). Additional protocols using commercially available reagents, such as Lipofectamine (Gibco/BRL) or Lipofectamine-Plus, can be used to transfect cells (Feigner et al., Proc. Natl. Acad. Sci. USA 84:7413, 1987). In addition, electroporation can be used to transfect mammalian cells using conventional procedures, such as those in Sambrook et al. Molecular Cloning: A Laboratory Manual, 2 ed. Vol. 1-3, Cold Spring Harbor Laboratory Press, 1989). Selection of stable transformants can be performed using methods known in the art, such as, for example, resistance to cytotoxic drugs. Kaufman et al., Meth. in Enzymology 185:487, 1990, describes several selection schemes, such as dihydrofolate reductase (DHFR) resistance. A suitable host strain for DHFR selection can be CHO strain DX-B 11, which is deficient in DHFR (Urlaub and Chasin; Proc. Natl. Acad. Sci. USA 77:4216, . 1980). A plasmid expressing the DHFR cDNA can be introduced into strain DX-B 11, and only cells that contain the plasmid can grow in the appropriate selective media. Other examples of selectable markers that can be incorporated into an expression vector include cDNAs conferring resistance to antibiotics, such as G418 and hygromycin B. Cells harboring the vector can be selected on the basis of resistance to these compounds.

[0077] Transcriptional and translational control sequences for mammalian host cell expression vectors can be excised from viral genomes. Commonly used promoter sequences and enhancer sequences are derived from polyoma virus, adenovirus 2, simian virus 40 (SV40), and human cytomegalovirus. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early and late promoter, enhancer, splice, and polyadenylation sites can be used to provide other genetic elements for expression of a structural gene sequence in a mammalian host cell. Viral early and late promoters are particularly useful because both are easily obtained from a viral genome as a fragment, which can also contain a viral origin of replication (Fiers et al., Nature 273:113, 1978; Kaufman, Meth. in Enzymology, 1990). Smaller or larger SV40 fragments can also be used, provided the approximately 250 bp sequence extending from the *Hind* III site toward the *Bgl* I site located in the SV40 viral origin of replication site is included.

[0078] Additional control sequences shown to improve expression of heterologous genes from mammalian expression vectors include such elements as the expression augmenting sequence element (EASE) derived from CHO cells (Morris et al., *Animal Cell Technology*, 1997, pp. 529-534) and the tripartite leader (TPL) and VA gene RNAs from Adenovirus 2 (Gingeras et al., *J. Biol. Chem.* 257:13475, 1982). The internal ribosome entry site (IRES) sequences of viral origin allows dicistronic mRNAs to be translated efficiently (Oh and Sarnow, *Current Opinion in Genetics and Development* 3: 295, 1993; Ramesh et al., *Nucleic Acids Research* 24:2697, 1996). Expression of a heterologous cDNA as part of a dicistronic mRNA followed by the gene for a selectable marker (e.g. DHFR) has been shown to improve transfectability of the host and expression of the heterologous cDNA (Kaufman, *Meth. in Enzymology*, 1990). Exemplary expression vectors that employ dicistronic mRNAs are pTR-DC/GFP described by Mosser et al., *Biotechniques* 22:150, 1997, and p2A51 described by Morris et al., *Animal Cell Technology*, 1997, pp. 529-534.

[0079] A useful high expression vector, pCAVNOT, has been described by Mosley et al., *Cell* 59:335, 1989. Other expression vectors for use in mammalian host cells can be constructed as disclosed by Okayama and Berg (*Mol. Cell. Biol.* 3:280, 1983). A useful system for stable high level expression of mammalian cDNAs in C127 murine mammary epithelial cells can be constructed substantially as described by Cosman et al. (*Mol. Immunol.* 23:935, 1986). A useful high expression vector, PMLSV N 1/N4, described by Cosman et al., *Nature* 312:768, 1984, has been deposited as ATCC 39890. Additional useful mammalian expression vectors are known in the art.

[0080] Regarding signal peptides that may be employed in producing Tek polypeptides, the native Tek signal peptide may be used or it may be replaced by a heterologous signal peptide or leader sequence, if desired. The choice of signal peptide or leader may depend on factors such as the type of host cells in which the recombinant Tek is to be produced. Examples of heterologous signal peptides that are functional in mammalian host cells include the signal sequence for interleukin-7 (IL-7) described in United States Patent 4,965,195, the signal sequence for interleukin-2 receptor described in Cosman et al., *Nature* 312:768 (1984); the interleukin-4 receptor signal peptide described in EP 367,566; the type I interleukin-1 receptor signal peptide described in U.S. Patent 4,968,607; and the type II interleukin-1 receptor signal peptide described in EP 460,846.

[0081] Using the techniques of recombinant DNA including mutagenesis and the polymerase chain reaction (PCR), the skilled artisan can produce DNA sequences that encode Tek polypeptides comprising various additions or substitutions of amino acid residues or sequences, or deletions of terminal or internal residues or sequences, including Tek fragments, variants, derivatives, and fusion polypeptides.

[0082] Transgenic animals, including mice, goats, sheep, and pigs, and transgenic plants, including tobacco, tomato, legumes, grasses, and grains, may also be used as bioreactors for the production of Tek polypeptides, including soluble Tek polypeptides. In the case of transgenic animals, it is particularly advantageous to construct a chimeric DNA including a Tek coding sequence operably linked to cis-acting regulatory sequences that promote expression of the soluble Tek in milk and/or other body fluids (see, e.g., U.S. Patent No. 5,843,705; U.S. Patent No. 5,880,327). In the case of transgenic plants it is particularly advantageous to produce Tek in a particular cell type, tissue, or organ (see, e.g., U.S. Patent No. 5,639,947; U.S. Patent No. 5,889,189).

[0083] The skilled artisan will recognize that the procedure for purifying expressed soluble Tek polypeptides will vary according to the host system employed, and whether or not the recombinant polypeptide is secreted. Soluble Tek polypeptides may be purified using methods known in the art, including one or more concentration, salting-out, ion exchange, hydrophobic interaction, affinity purification, HPLC, or size exclusion chromatography steps. Fusion polypeptides comprising Fc moieties (and multimers formed therefrom) offer the advantage of facile purification by affinity chromatography over Protein A or Protein G columns.

E. Tek Antibodies

[0084] Antigenic epitopes of the Tek extracellular domain are useful for raising antibodies, and in particular the blocking monoclonal antibodies described in more detail below. Such epitopes or variants thereof can be produced using techniques well known in the art such as solid-phase synthesis, chemical or enzymatic cleavage of a polypeptide, or using recombinant DNA technology. As exemplified below, the Inventors have determined that the Tek extracellular domain comprises at least three epitopes, and that antibodies generated against a deleted form of the Tek extracellular domain can compete with Tek ligands for binding to Tek.

[0085] Compositions and uses of antibodies that are immunoreactive with Tek polypeptides are described herein. Such antibodies "bind specifically" to Tek polypeptides, meaning that they bind via antigen-binding sites of the antibody as compared to non-specific binding interactions. The terms "antibody" and "antibodies" are used herein in their broadest sense, and include, without limitation, intact monoclonal and polyclonal antibodies as well as fragments such as Fv, Fab, and F(ab')₂ fragments, single-chain antibodies such as scfv, and various chain combinations. The antibodies may be humanized, and may be human. The antibodies may be prepared using a variety of well-known methods including, without limitation, immunization of animals having native or transgenic immune repertoires, phage display, hybridoma and recombinant cell culture, and transgenic plant and animal bioreactors.

[0086] Both polyclonal and monoclonal antibodies may be prepared by conventional techniques. See, for example, *Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses*, Kennet et al. (eds.), Plenum Press, New York (1980); and *Antibodies: A Laboratory Manual*, Harlow and Land (eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1988).

[0087] Hybridoma cell lines that produce monoclonal antibodies specific for the polypeptides of the invention are also described herein. Such hybridomas may be produced and identified by conventional techniques. One method for producing such a hybridoma cell line comprises immunizing an animal with a polypeptide, harvesting spleen cells from the immunized animal, fusing said spleen cells to a myeloma cell line, thereby generating hybridoma cells, and identifying a hybridoma cell line that produces a monoclonal antibody that binds the polypeptide. The monoclonal antibodies produced by hybridomas may be recovered by conventional techniques.

[0088] The monoclonal antibodies include chimeric antibodies, e.g., "humanized" versions of antibodies originally produced in mice or other non-human species. A humanized antibody is an engineered antibody that typically comprises the variable region of a non-human (e.g., murine) antibody, or at least complementarity determining regions (CDRs) thereof, and the remaining immunoglobulin portions derived from a human antibody. Procedures for the production of chimeric and further engineered monoclonal antibodies include those described in Riechmann et al. (*Nature* 332:323, 1988), Liu et al. (*PNAS* 84:3439, 1987), Larrick et al. (*Bio/technology* 7:934, 1989), and Winter and Harris (*TIPS* 14: 139, May, 1993). Such humanized antibodies may be prepared by known techniques and offer the advantage of reduced immunogenicity when the antibodies are administered to humans.

[0089] Procedures that have been developed for generating human antibodies in non-human animals may be employed in producing antibodies. The antibodies may be partially human or preferably completely human. For example, transgenic mice into which genetic material encoding one or more human immunoglobulin chains has been introduced may be employed. Such mice may be genetically altered in a variety of ways. The genetic manipulation may result in human immunoglobulin polypeptide chains replacing endogenous immunoglobulin chains in at least some, and preferably virtually all, antibodies produced by the animal upon immunization.

[0090] Mice in which one or more endogenous immunoglobulin genes have been inactivated by various means have been prepared. Human immunoglobulin genes have been introduced into the mice to replace the inactivated mouse genes. Antibodies produced in the animals incorporate human immunoglobulin polypeptide chains encoded by the human genetic material introduced into the animal. Examples of techniques for the production and use of such transgenic animals to make antibodies (which are sometimes called "transgenic antibodies") are described in U.S. Patent Nos. 5,814,318, 5,569,825, and 5,545,806,.

F. Therapeutic Methods

[0091] The disclosed polypeptides may be used to inhibit angiogenesis or other Tek-mediated responses in a mammal in need of such treatment. The term "Tek-mediated response" includes any cellular, physiological, or other biological response that is caused at least in part by the binding of A Tek ligand to Tek, or which may be inhibited or suppressed, in whole or in part, by blocking a Tek ligand from binding to Tek. The treatment is advantageously administered in order to prevent the onset or the recurrence of a disease or condition mediated by angiogenesis, or to treat a mammal that has a disease or condition mediated by angiogenesis. Diseases and conditions mediated by angiogenesis include but are not limited to ocular disorders, malignant and metastatic conditions, and inflammatory diseases.

[0092] Among the ocular disorders that can be treated according to the present invention are eye diseases characterized by ocular neovascularization including, but not limited to, diabetic retinopathy (a major complication of diabetes), retinopathy of prematurity (this devastating eye condition, that frequently leads to chronic vision problems and carries a high risk of blindness, is a severe complication during the care of premature infants), neovascular glaucoma, retinoblastoma, retrolental fibroplasia, rubeosis, uveitis, macular degeneration, and corneal graft neovascularization. Other eye inflammatory diseases, ocular tumors, and diseases associated with choroidal or iris neovascularization can also be treated according to the present invention.

[0093] The present invention can also be used to treat malignant and metastatic conditions such as solid tumors. Solid tumors include both primary and metastatic sarcomas and carcinomas.

[0094] The present invention can also be used to treat inflammatory diseases including, but not limited to arthritis, rheumatism, and psoriasis.

[0095] Other diseases and conditions that can be treated according to the present invention include benign tumors and preneoplastic conditions, myocardial angiogenesis, hemophilic joints, scleroderma, vascular adhesions, atherosclerotic plaque neovascularization, telangiectasia, and wound granulation.

[0096] In addition to polypeptides comprising a fragment of Tek extracellular domain, soluble Tek multimers, and antibodies that bind to the Tek extracellular domain, other forms of Tek antagonists can also be administered to achieve a therapeutic effect. Examples of other forms of Tek antagonists include other antibodies such as antibodies against a Tek ligand, antisense nucleic acids, ribozymes, muteins, aptamers, and small molecules directed against Tek or against

one or more of the Tek ligands.

[0097] The polypeptides or multimers according to the present invention can be tested in in vivo animal models to confirm the desired prophylactic or therapeutic activity, as well as to determine the optimal therapeutic dosage, prior to administration to humans.

[0098] The amount of a particular Tek antagonist that will be effective in a particular method of treatment depends upon age, type and severity of the condition to be treated, body weight, desired duration of treatment, method of administration, and other parameters. Effective dosages are determined by a physician or other qualified medical professional. Typical effective dosages are about 0.01 mg/kg to about 100 mg/kg body weight. In some preferred embodiments the dosage is about 0.1-50 mg/kg; in some preferred embodiments the dosage is about 0.5-10 mg/kg. The dosage for local administration is typically lower than for systemic administration. In some embodiments a single administration is sufficient; in some embodiments the Tek antagonist is administered as multiple doses over one or more days.

[0099] The Tek antagonists are typically administered in the form of a pharmaceutical composition comprising one or more pharmacologically acceptable carriers. Pharmaceutically acceptable carriers include diluents, fillers, adjuvants, excipients, and vehicles which are pharmaceutically acceptable for the route of administration, and may be aqueous or oleaginous suspensions formulated using suitable dispersing, wetting, and suspending agents.

[0100] Pharmaceutically acceptable carriers are generally sterile and free of pyrogenic agents, and may include water, oils, solvents, salts, sugars and other carbohydrates, emulsifying agents, buffering agents, antimicrobial agents, and chelating agents. The particular pharmaceutically acceptable carrier and the ratio of active compound to carrier are determined by the solubility and chemical properties of the composition, the mode of administration, and standard pharmaceutical practice.

[0101] The Tek antagonists are administered to the patient in a manner appropriate to the indication. Thus, for example, a Tek antagonist, or a pharmaceutical composition thereof, may be administered by intravenous, transdermal, intradermal, intraperitoneal, intramuscular, intranasal, epidural, oral, topical, subcutaneous, intracavity, sustained release from implants, peristaltic routes, or by any other suitable technique. Parenteral administration is preferred.

[0102] The mammal may be treated with one or more additional chemotherapeutic agents. The additional chemotherapeutic agent(s) may be administered prior to, concurrently with, or following the administration of the Tek antagonist. The use of more than one chemotherapeutic agent is particularly advantageous when the mammal that is being treated has a solid tumor. The mammal may be treated with radiation. Radiation, including brachytherapy and teletherapy, may be administered prior to, concurrently with, or following the administration of the second chemotherapeutic agent(s) and/or Tek antagonist.

[0103] When the mammal that is being treated has a solid tumor, in addition to a Tek antagonist, one or more chemotherapeutic agents selected from the group consisting of alkylating agents, anti metabolites, vinca alkaloids and other plant-derived chemotherapeutics, nitrosoureas, antitumor antibiotics, antitumor enzymes, topoisomerase inhibitors, platinum analogs, adrenocortical suppressants, hormones, hormone agonists and antagonists, antibodies, immunotherapeutics, blood cell factors, radiotherapeutics, and biological response modifiers may be administered.

[0104] In addition to a Tek antagonist, one or more chemotherapeutic agents selected from the group consisting of cisplatin, cyclophosphamide, mechlorethamine, melphalan, bleomycin, carboplatin, fluorouracil, 5-fluorodeoxyuridine, methotrexate, taxol, asparaginase, vincristine, and vinblastine, lymphokines and cytokines such as interleukins, interferons (including alpha, beta, or delta), and TNF, chlorambucil, busulfan, carmustine, lomustine, semustine, streptozocin, dacarbazine, cytarabine, mercaptopurine, thioguanine, vindesine, etoposide, teniposide, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin, mitomycin, L-asparaginase, hydroxyurea, methylhydrazine, mitotane, tamoxifen, and fluoxymesterone may be administered.

[0105] In addition to a Tek antagonist, one or more chemotherapeutic agents, including various soluble forms thereof, selected from the group consisting of Flt3 ligand, CD40 ligand, interleukin-2, interleukin-12, 4-1BB ligand, anti-4-1BB antibodies, TNF antagonists and TNF receptor antagonists, TRAIL, VEGF antagonists, VEGF receptor (including VEGF-R1 and VEGF-R2, also known as Flt1 and Flk1 or KDR) antagonists, and CD148 (also referred to as DEP-1, ECRTF, and PTPRJ, see Takahashi et al., J. Am. Soc. Nephrol. 10:2135-45, 1999) agonists may be administered.

[0106] The Tek antagonists of the invention may be used as a component of, or in combination with, "metronomic therapy," such as that described by Browder et al. and Klement et al. (Cancer Research 60:1878, 2000; J. Clin. Invest. 105(8):R15, 2000; see also Barinaga, Science 288:245, 2000).

[0107] The polypeptides of the present invention may be used as a first line treatment, for the treatment of residual disease following primary therapy, or as an adjunct to other therapies including chemotherapy, surgery, radiation, and other therapeutic methods known in the art.

EXAMPLES

[0108] The following examples are intended to illustrate particular embodiments and not to limit the scope of the invention.

EXAMPLE 1**Recombinant Production of Soluble Tek/Fc Fusion Polypeptides**

[0109] The molecular cloning of a cDNA encoding the human receptor tyrosine kinase (RTK) Tek (ork, Tie3) is described in U.S. Patent No. 5,447,860. The Tek cDNA (deposited with the American Type Culture Collection under the terms of the Budapest Treaty on 28 May 1992, Accession No. ATCC 69003) encodes 1124 amino acids, including a signal peptide, an N-terminal extracellular domain, a transmembrane domain, and a C-terminal cytoplasmic domain. Based on sequence analysis, the signal peptide is predicted to encompass residues 1-18, the N-terminal extracellular domain is predicted to encompass residues 19-745, the transmembrane domain is predicted to encompass residues 746-772, and the C-terminal cytoplasmic domain is predicted to encompass residues 773-1124. The extracellular domain includes two immunoglobulin (Ig)-like loops, a region containing three EGF-like cysteine repeats (between residues 211-340), and a region containing three fibronectin type III (FNIII) motifs (between residues 440-733). Tek cDNA was used to construct recombinant expression vectors for the production of various Tek/Fc fusion polypeptides.

[0110] To construct a nucleic acid encoding the full length Tek extracellular domain fused to Fc, a nucleic acid encoding the N-terminal 745 amino acids from Tek, including the Tek leader (signal peptide) and extracellular domain, was fused to a nucleic acid encoding a 232 amino acid Fc portion from human IgG 1. The amino acid sequence of the Tek/Fc fusion polypeptide encoded by this construct is shown as SEQ ID NO:1. In SEQ ID NO:1, residues 1-18 are the predicted signal peptide (predicted to be cleaved upon secretion from the cell; the actual cleavage site was identified by N-terminal sequence analysis, see below), residues 19-745 are the Tek extracellular domain, and residues 746-977 are the Fc portion. Upon insertion into a mammalian expression vector, and expression in and secretion from a mammalian host cell, this construct produced a polypeptide designated Tek745/Fc. Based on the predicted signal peptide cleavage site, the amino acid sequence of Tek745/Fc was predicted to be residues 19-997 of SEQ ID NO:1.

[0111] To construct a nucleic acid encoding a fragment of the Tek extracellular domain fused to Fc, a nucleic acid encoding the N-terminal 472 amino acids from Tek, including the Tek leader (signal peptide) and a deleted extracellular domain, was fused to a nucleic acid encoding a 232 amino acid Fc portion from human IgG 1. The amino acid sequence of the Tek/Fc fusion polypeptide encoded by this construct is shown as SEQ ID NO:2. In SEQ ID NO:2, residues 1-18 are the predicted signal peptide (predicted to be cleaved upon secretion from the cell; the actual cleavage site was identified by N-terminal sequence analysis, see below), residues 19-472 are the fragment of the Tek extracellular domain, and residues 473-704 are the Fc portion. Upon insertion into a mammalian expression vector, and expression in and secretion from a mammalian host cell, this construct produced a polypeptide designated Tek472/Fc. Based on the predicted signal peptide cleavage site, the amino acid sequence of Tek472/Fc was predicted to be residues 19-704 of SEQ ID NO:2.

[0112] Nucleic acids encoding each of the Tek/Fc fusion polypeptides were inserted into mammalian expression vectors, and each vector was transfected into CHO cells. After amplification, stably transfected CHO cell lines were cultured under conditions promoting the expression and secretion of the recombinant fusion polypeptides and the Tek/Fc fusion polypeptides were recovered and isolated from the culture medium. N-terminal sequence analysis determined that the secreted polypeptide designated Tek745/Fc had an N-terminus corresponding to residue 23 (alanine) of SEQ ID NO:1. N-terminal sequence analysis determined that the secreted polypeptide designated Tek472/Fc had an N-terminus corresponding to residue 23 (alanine) of SEQ ID NO:2.

[0113] Anti-angiogenic activity of the Tek/Fc fusion polypeptides is demonstrated in the in vitro and in vivo systems described in Examples 2-6.

EXAMPLE 2**Activity of Tek/Fc In a Wound Closure Assay**

[0114] A planar endothelial cell migration (wound closure) assay was used to quantitate the inhibition of angiogenesis by Tek/Fc in vitro. In this assay, endothelial cell migration is measured as the rate of closure of a circular wound in a cultured cell monolayer. The rate of wound closure is linear, and is dynamically regulated by agents that stimulate and inhibit angiogenesis in vivo.

[0115] Primary human renal microvascular endothelial cells, HRMEC, were isolated, cultured, and used at the third passage after thawing, as described in Martin et al., *In Vitro Cell Dev Biol* 33:261, 1997. Replicate circular lesions, "wounds," (600-800 micron diameter) were generated in confluent HRMEC monolayers using a silicon-tipped drill press. At the time of wounding the medium (DMEM + 1 % BSA) was supplemented with 20 ng/ml PMA (phorbol-12-myristate-13-acetate), 10 μ g/ml Tek472/Fc, or combinations of 20 ng/ml PMA and 0.001-10 μ g/ml Tek472/Fc. The residual wound area was measured as a function of time (0-12 hours) using a microscope and image analysis software (Bioquant, Nashville, TN). The relative migration rate was calculated for each agent and combination of agents by linear regression

of residual wound area plotted over time. The results are shown in Figure 1. Tek472/Fc inhibited PMA-induced endothelial migration in a dose responsive manner, reducing the rate of migration to unstimulated levels at 10 $\mu\text{g/ml}$.

EXAMPLE 3

Activity of Tek/Fc In a Corneal Pocket Assay

[0116] A mouse corneal pocket assay was used to quantitate the inhibition of angiogenesis by Tek/Fc in vivo. In this assay, agents to be tested for angiogenic or anti-angiogenic activity are immobilized in a slow release form in a hydon pellet, which is implanted into micropockets created in the corneal epithelium of anesthetized mice. Vascularization is measured as the appearance, density, and extent of vessel ingrowth from the vascularized corneal limbus into the normally avascular cornea.

[0117] Hydon pellets, as described in Kenyon et al., Invest Ophthalmol. & Visual Science 37:1625, 1996, incorporated sucralfate with bFGF (90 ng/pellet), bFGF and IgG (11 $\mu\text{g/pellet}$, control), or bFGF and Tek472/Fc (12.8 μg). The pellets were surgically implanted into corneal stromal micropockets created by micro-dissection 1mm medial to the lateral corneal limbus of 6-8 week old male C57BL mice. After five days, at the peak of neovascular response to bFGF, the corneas were photographed, using a Zeiss slit lamp, at an incipient angle of 35-50° from the polar axis in the meridian containing the pellet. Images were digitized and processed by subtractive color filters (Adobe Photoshop 4.0) to delineate established microvessels by hemoglobin content. Image analysis software (Bioquant, Nashville, TN) was used to calculate the fraction of the corneal image that was vascularized, the vessel density within the vascularized area, and the vessel density within the total cornea. The results are shown in Figure 2. Tek472/Fc (50 pmol) inhibited bFGF (3 pmol)-induced corneal angiogenesis, reducing the vascular density to 30% of that induced by FGF alone.

EXAMPLE 4

Inhibition of Neovascularization by Tek/Fc in a Murine Transplant Model

[0118] Survival of heterotopically transplanted cardiac tissue from one mouse donor to the ear skin of another genetically similar mouse requires adequate neovascularization by the transplanted heart and the surrounding tissue, to promote survival and energy for cardiac muscle function. Inadequate vasculature at the site of transplant causes excessive ischemia to the heart, tissue damage, and failure of the tissue to engraft. Agents that antagonize the angiopoietins and endothelial specific factors involved in endothelial cell migration and vessel formation can decrease angiogenesis at the site of transplant, thereby limiting graft tissue function and ultimately engraftment itself.

[0119] The following studies were carried out, utilizing a murine heterotopic cardiac isograft model, in order to demonstrate the antagonistic effects of Tek/Fc on neovascularization. In all experiments, female BALB/c (=12 weeks of age) recipients received neonatal heart grafts from donor mice of the same strain.

A. Tek/Fc at 500 $\mu\text{g/Day}$ Dose

[0120] In each of three experiments, the donor heart tissue was engrafted into the left ear pinnae of the recipient on day 0 and the mice were divided into two groups. The control group received human IgG (Hu IgG) while the other group received human Tek472/Fc, both intraperitoneally at 500 μg per day. All treatments began on day 0 and continued for five consecutive days. The functionality of the grafts was determined by monitoring visible pulsatile activity on days 7 and 14 post-engraftment. Table 1 shows the cumulative results from the three experiments.

Table 1 Functional Engraftment at Days 7 and 14

Total	Treatment	Day 7	Day 14
N = 8	Hu IgG	8/8 (100%)	8/8 (100%)
N=11	Tek472/Fc	4/11 (36%)	9/11(82%)

[0121] All 8 mice receiving Hu IgG had functioning grafts on days 7 and 14, indicating 100% engraftment. The Tek472/Fc treated mice initially demonstrated no functional activity, indicative of diminished engraftment, with only 36% having functioning grafts at day 7. By day 14, ten days after cessation of Tek472/Fc treatment, 82% of the mice had functioning grafts.

[0122] Histological studies on the transplanted hearts of mice receiving the Tek/Fc showed increased edema at the site of transplant, indicative of vascular leakage, and decreased host and donor tissue vasculature staining (Factor VIII)

as compared to that observed in transplanted hearts from mice receiving the control protein IgG.

[0123] This experiment showed that treatment with Tek472/Fc severely compromised cardiac isograft function and prevented engraftment of tissue in 64% of mice at day 7 after a 5 day course of therapy.

B. Tek/Fc Dose Titration

[0124] Three different doses of Tek/Fc were tested in the cardiac isograft model described above. Each test group contained four female BALB/c mice. The control group received human IgG (Hu IgG), intraperitoneally, at 500 µg per day for five consecutive days. The Tek/Fc groups received human Tek472/Fc, intraperitoneally, at 90, 250, or 500 µg per day for five consecutive days. The functionality of the grafts was determined by monitoring visible pulsatile activity on post-engraftment days 7, 11, 14, 17, and 21. The results are shown in Table 2.

Table 2 Functional Engraftment Following Dose Titration with Tek

Treatment	Day 7	Day 11	Day 14	Day 17	Day 21
Hu IgG 500 µg	100*	100	100	100	100
Tek472/Fc 90 µg	75	00	100	100	100
Tek472/Fc 250 µg	25	75	75	100	100
Tek472/Fc 500 µg	25	75	75	75	75
*all results are reported as percent of mice with pulsatile heart grafts					

[0125] A similar magnitude of cardiac isograft engraftment disruption was observed at both the 250 µg and 500 µg doses of Tek/Fc, as compared to Hu IgG control where no effect on engraftment was observed. A small, albeit significantly insignificant, reduction in engraftment was observed at the 90 µg dose.

EXAMPLE 5

Treatment of Tumors With Tek472/Fc

[0126] Tek472/Fc was administered alone, and in combination with Flt3L, to treat mice bearing 87 fibrosarcoma or B 10.2 fibrosarcoma tumors. The B10.2 and 87 tumors are of the progressor phenotype, i.e. they grow progressively in normal mice. The B 10.2 fibrosarcoma was induced by subcutaneous implantation of a paraffin pellet containing 5 mg of methylcholanthrene in C57BL mice (Lynch and Miller, Eur. J. Immunol., 21:1403, 1991). The 87 fibrosarcoma is a progressor variant of a tumor induced by chronic exposure of C3H/HeN mice to UVB irradiation. To inoculate tumors in mice for these experiments, 5×10^5 cells were injected (day 0) intradermally in the abdomen (see, also, Borges et al., J. Immunol. 163:1289, 1999).

[0127] The 87 fibrosarcoma tumors in C3H/HeN mice were treated with MSA (murine serum albumin, control), Tek/Fc (312 µg/day, days 4-19 after tumor cell injection), Flt3L (10 µg/day, days 1-19 after tumor cell injection), or a combination of Tek/Fc and Flt3L (Tek/Fc at 312 µg/day, days 4-19; Flt3L at 10 µg/day, days 1-19 after tumor cell injection). Each treatment group consisted of ten mice. Tumor frequency and tumor size were measured weekly for five weeks. The results are shown in Figure 3. Mice treated with the combination of Tek/Fc and Flt3L showed the slowest tumor growth rates. In week 6 an additional animal in the Tek/Fc plus Flt3L group rejected the tumor, decreasing the tumor frequency to 68%. Based upon the results of this experiment, the combination of Tek/Fc and Flt3L was used to treat pre-existing B 10.2 fibrosarcoma tumors.

[0128] The B10.2 fibrosarcoma tumors in C57BL/10 mice were treated with MSA (control), Tek/Fc (625 µg/day, days 7-32 after tumor cell injection), Flt3L (10 µg/day, days 7-26 after tumor cell injection), or a combination of Tek/Fc and Flt3L (Tek/Fc at 312.5 or 625 µg/day, days 7-32; Flt3L at 10 µg/day, days 7-26 after tumor cell injection). Each treatment group consisted of ten mice. Tumor frequency and tumor size were measured weekly for six weeks. The results are shown in Figure 4. Mice treated with both combinations of Tek/Fc and Flt3L showed reduced tumor growth rates; mice treated with 625 µg/day Tek/Fc in combination with Flt3L showed the slowest tumor growth rate.

EXAMPLE 6**Binding of Tek/Fc Fusion Polypeptides to Angiopoietin**

[0129] Both Tek745/Fc and Tek472/Fc were examined for the ability to bind the human Tek ligand angiopoietin 2 (Ang2), using a solid-phase plate binding assay based on time-resolved fluorescence. Comparison of binding to human Ang2 with the two different forms of soluble Tek/Fc revealed that Tek472/Fc bound significantly better (21-fold better) to Ang2 than did Tek745/Fc.

[0130] Low fluorescence 8x12 strip microtiter plate wells (Perkin-Wallac, Ackron, Ohio) were incubated with human Ang2 (R&D systems) at 500 ng/ml (100 μ l) overnight at 2-8° C. The wells were then blocked by the addition of 100 μ l of 1% BSA/PBS solution for 1 hour at room temperature. Following a 4X PBS-T (PBS-Tween 20 0.05%) wash, samples containing Tek745/Fc, Tek472/Fc, or TNFR/Fc (control/Fc) were titrated in diluent (1% BSA/PBS), in duplicate, beginning at 30 μ g/ml in 3-fold dilutions. The samples were allowed to bind for 1 hour at room temperature with gentle agitation and then the unbound material was washed away 4X with PBS-T. Bound Tek/Fc was detected by adding goat anti human IgG-Europium conjugate (Perkin-Wallac), diluted to 100 μ g/ml in assay buffer, to the wells and incubating for 30 minutes at room temperature. Unbound goat anti-human IgG-Europium was removed by a 4X PBS-T wash. Following the wash 150 μ l of Enhancement solution (Perkin Wallac) was added to each well and the plate allowed to incubate at room temperature for a minimum of 5 minutes. Binding was determined by reading the fluorescence emitted from each well on a Victor II Multilabel counter equipped with software and light excitation/emission devices to measure Europium-derived fluorescence. The results, expressed as fluorescence counts, are shown in Figure 5.

[0131] The TNFR/Fc control did not exhibit detectable binding (over that observed for background) to human Ang2. Both Tek472/Fc and Tek745/Fc bound to human Ang2 in a concentration dependent manner, but Tek472/Fc had a higher binding affinity. Tek472/Fc bound greater than 20-fold better than Tek745/Fc, based on mass concentration. Much higher concentrations of Tek745/Fc were required to achieve the same level of binding observed at lower concentrations of Tek472/Fc. The BC40K (the concentration of Tek/Fc required to achieve 40,000 fluorescence counts of huANG-2 binding) for Tek745/Fc was 20,596 ng/ml, compared to the BC40K for Tek472/Fc which was 994 ng/ml.

EXAMPLE 7**Tek-Specific Blocking Monoclonal Antibodies**A. Antibodies to Tek472/Fc

[0132] Antibodies against "recombinant Tie2 extracellular domain-Fc fusion" have been described by Holmes et al., WO 00/18437. The present Inventors, in contrast, made antibodies against the deleted Tek extracellular domain fusion polypeptide Tek472/Fc. As shown in example 6, Tek472/Fc binds Tek ligand with higher affinity than does Tek745/Fc.

[0133] BALB/c mice were immunized with the Tek/Fc fusion polypeptide Tek472/Fc described in Example 1. Spleen cells were collected and used to prepare hybridomas using standard procedures. Hybridoma supernatants were screened, using ELISA, for the ability to bind (a) Tek472/Fc and (b) CV 1 cells expressing human Tek. Positives were cloned two times, to insure monoclonality, then isotyped and reassayed for reactivity to Tek.

[0134] Three antibodies were chosen for further experiments: M530 (IgG2b isotype), M531 (IgG2b isotype), and M532 (IgG1 isotype). M530 and M531 appear to recognize the same epitope and M532 recognizes a second (different) epitope. M530 and M532 were therefore used as an antibody pair (e.g., for capture and detection) in various immunoassays. M530 was shown (by immunoprecipitation and by solid phase plate binding assays) to bind Tek745/Fc, Tek472/Fc, and to bind to naturally occurring Tek as expressed on the surface of human endothelial cells. The M530 antibody was further characterized in the binding and epitope mapping studies described in Example 8, below.

B. Additional Tek Antibodies

[0135] A workshop panel of putative endothelial cell-specific antibodies, which were not yet clustered, was obtained from the Human Leukocyte Differentiation Antigens (HLDA) Workshop. Some of the antibodies were generated by immunizing mice with human endothelial cells. One antibody in the panel was known to react with human Tek. These antibodies were further characterized in the binding and epitope mapping studies described in Example 8, below.

EXAMPLE 8**Tek Antibody Binding to Tek and to Human Microvascular Endothelial Cells**A. Antibody Binding to Full Length Tek Extracellular Domain and to Endothelial Cells

[0136] Using a solid phase binding assay (time resolved fluorescence, as described in Example 6), the huTek monoclonal antibody M530 described in Example 7A and eight monoclonal antibodies described in Example 7B (endothelial cell-specific antibodies numbered WS#70098, #70099, #70100, #70101, #70104, #70108, #70112, and putative Tek-specific antibody #70637) bound specifically to the full length Tek extracellular fusion polypeptide Tek745/Fc. An IgG1 negative control mAb (MOPC21) did not bind to Tek745/Fc over background. Two other endothelial cell-specific workshop antibodies (WS#70110 and #70115 did not detectably bind to Tek745/Fc.

[0137] Using flow cytometry, the human Tek monoclonal antibodies M530, M531, and M532 described in Example 7A and eight monoclonal antibodies described in Example 7B (endothelial cell-specific antibodies numbered #70098, #70099, #70100, #70101, #70104, #70108, #70112, and Tek-specific antibody #70637) were shown to bind to naturally occurring Tek as expressed on human endothelial cells (both human microvascular endothelial cells from adult skin and HUVEC).

B Antibody Binding to a Tek Extracellular Domain Lacking FN3 Motifs

[0138] The monoclonal antibody M530 described in Example 7A and seven monoclonal antibodies described in Example 7B (endothelial cell-specific antibodies numbered #70098, #70099, #70100, #70101, #70104, #70108, and #70112) bound specifically to the deleted Tek extracellular fusion polypeptide Tek472/Fc. Workshop antibodies #70637 (which bound to Tek745/Fc), #70110, and #70115 did not bind to Tek472/Fc.

C Competitive Inhibition of Antibody Binding by Tek Ligands

[0139] Angiopoietin-1 (Ang1, Davis et al., Cell 87:1161, 1996) and Angiopoietin-2 (Ang2, Maisonpierre et al., Science 277:55, 1997) are two closely related Tek ligands. Both Ang1 and Ang2 bind with similar affinity to human Tek. The addition of a molar excess of Ang2 to EC cultures in the presence of Ang1 has been shown to inhibit Ang1 induced activation of Tek on endothelial cells via competition of Ang1 binding to endothelial cells (Maisonpierre et al., Science 277:55, 1997). A recombinant human angiopoietin-2 preparation was obtained from R&D Systems, Inc. (Minneapolis, MN). According to the manufacturer, the angiopoietin-2 preparation migrates as a 66 kDa protein in SDS-PAGE under both reducing and non-reducing conditions. Based on N-terminal amino acid sequencing, the preparation contains two peptides: a major polypeptide (75.% of the total) having Asp68 as its N-terminus and a minor polypeptide (25% of the total) having Tyr19 as its N-terminus:

[0140] The ability of this Ang2 preparation to competitively inhibit the binding of Tek antibodies to Tek expressed on skin human microvascular endothelial cells was tested using flow cytometry.

[0141] Each mAb was added to 500,000 HMVEC-d at 5 µg/ml in 12x75mm falcon tubes in duplicate and allowed to incubate for 15 minutes at 4° C in binding medium. To one set of the duplicates, human Ang2 was added at 10 µg/ml (a five-fold molar excess) for an additional 30 minutes. The cells with the bound Tek mAb were then washed in 20 volumes of PBS-containing wash buffer. After the wash step, bound mouse mAb was detected by the addition of F(ab*2) sheep anti mouse IgG-PE fluorescent conjugate to the cells, followed by a 30 minute incubation at 4° C and an additional 20 volume wash. Binding of the Tek mAb was measured by flow cytometric analysis on a single-laser FACSCAN (Becton Dickinson, Sunnyvale CA). The percent inhibition of antibody binding was calculated using the formula:

$$\text{MFI (no Ang2) - MFI (+Ang2)} / \text{MFI (noAng2)} \times 100.$$

The results are shown in Table 3.

Table 3 Inhibition of Tek Antibody Binding by Ang2

Monoclonal Antibody 5 µg/ml	Percent Inhibition of Antibody Binding by Ang2
negative control (MOPC-21)	0
binding control (αvβ3)	6.4

(continued)

Monoclonal Antibody 5 μ g/ml	Percent Inhibition of Antibody Binding by Ang2
M530	41.6
#70098	45.9
#70099	44.4
#70100	0
#70101	38.7
#70104	6.3
#70108	50.8
#70112	47.6
#70637	0

[0142] These results, inhibition of Tek antibody binding by Ang2, suggest that the M530, #70098, #70099, #70101, #70108, and #70112 antibodies bind at or near the Tek ligand binding site. The mAbs M530, WS#70099 and #70112 were also able to inhibit Ang2 binding (100 ng/ml) to recombinant human Tek472/Fc, by greater than 50% for mAb M530 and #70112 at concentrations of 10 μ g/ml or greater and for mAb 70099 at concentrations of 3 μ g/ml or greater.

[0143] In combination the binding results described in this example define at least three antibody epitopes in the human Tek extracellular domain, and exemplify the utility of preparing antibodies using a fragment of the Tek extracellular domain that lacks all or part of the region containing fibronectin type III (FNIII) motifs as an immunogen/target.

SEQUENCE LISTING

[0144]

<110> Immunex Corporation
Cerretti, Douglas P.
Borge, Luis G.
Fanslow, III, William C.

<120> TEK ANTAGONISTS

<130> 2900-WO

<140>

<141>

<150> 60/137,889

<151> 1999-06-07

<160> 2

<170> PatentIn Ver. 2.0

<210> 1

<211> 977

<212> PRT

<213> Homo sapiens

<400> 1

EP 1 187 918 B9

Met Asp Ser Leu Ala Ser Leu Val Leu Cys Gly Val Ser Leu Leu Leu
1 5 10 15
5 Ser Gly Thr Val Glu Gly Ala Met Asp Leu Ile Leu Ile Asn Ser Leu
20 25 30
Pro Leu Val Ser Asp Ala Glu Thr Ser Leu Thr Cys Ile Ala Ser Gly
35 40 45
10 Trp Arg Pro His Glu Pro Ile Thr Ile Gly Arg Asp Phe Glu Ala Leu
50 55 60
Met Asn Gln His Gln Asp Pro Leu Glu Val Thr Gln Asp Val Thr Arg
65 70 75 80
15 Glu Trp Ala Lys Lys Val Val Trp Lys Arg Glu Lys Ala Ser Lys Ile
85 90 95
Asn Gly Ala Tyr Phe Cys Glu Gly Arg Val Arg Gly Glu Ala Ile Arg
100 105 110
20 Ile Arg Thr Met Lys Met Arg Gln Gln Ala Ser Phe Leu Pro Ala Thr
115 120 125
Leu Thr Met Thr Val Asp Lys Gly Asp Asn Val Asn Ile Ser Phe Lys
130 135 140
25 Lys Val Leu Ile Lys Glu Glu Asp Ala Val Ile Tyr Lys Asn Gly Ser
145 150 155 160
Phe Ile His Ser Val Pro Arg His Glu Val Pro Asp Ile Leu Glu Val
165 170 175
30 His Leu Pro His Ala Gln Pro Gln Asp Ala Gly Val Tyr Ser Ala Arg
180 185 190
Tyr Ile Gly Gly Asn Leu Phe Thr Ser Ala Phe Thr Arg Leu Ile Val
195 200 205

	Arg	Arg	Cys	Glu	Ala	Gln	Lys	Trp	Gly	Pro	Glu	Cys	Asn	His	Leu	Cys
	210						215					220				
5	Thr	Ala	Cys	Met	Asn	Asn	Gly	Val	Cys	His	Glu	Asp	Thr	Gly	Glu	Cys
	225					230					235					240
	Ile	Cys	Pro	Pro	Gly	Phe	Met	Gly	Arg	Thr	Cys	Glu	Lys	Ala	Cys	Glu
					245					250					255	
10	Leu	His	Thr	Phe	Gly	Arg	Thr	Cys	Lys	Glu	Arg	Cys	Ser	Gly	Gln	Glu
				260					265					270		
	Gly	Cys	Lys	Ser	Tyr	Val	Phe	Cys	Leu	Pro	Asp	Pro	Tyr	Gly	Cys	Ser
			275					280					285			
15	Cys	Ala	Thr	Gly	Trp	Lys	Gly	Leu	Gln	Cys	Asn	Glu	Ala	Cys	His	Pro
		290					295					300				
	Gly	Phe	Tyr	Gly	Pro	Asp	Cys	Lys	Leu	Arg	Cys	Ser	Cys	Asn	Asn	Gly
	305					310					315					320
20	Glu	Met	Cys	Asp	Arg	Phe	Gln	Gly	Cys	Leu	Cys	Ser	Pro	Gly	Trp	Gln
					325					330					335	
	Gly	Leu	Gln	Cys	Glu	Arg	Glu	Gly	Ile	Pro	Arg	Met	Thr	Pro	Lys	Ile
				340					345					350		
25	Val	Asp	Leu	Pro	Asp	His	Ile	Glu	Val	Asn	Ser	Gly	Lys	Phe	Asn	Pro
			355					360					365			
	Ile	Cys	Lys	Ala	Ser	Gly	Trp	Pro	Leu	Pro	Thr	Asn	Glu	Glu	Met	Thr
		370					375					380				
30	Leu	Val	Lys	Pro	Asp	Gly	Thr	Val	Leu	His	Pro	Lys	Asp	Phe	Asn	His
	385					390					395					400
	Thr	Asp	His	Phe	Ser	Val	Ala	Ile	Phe	Thr	Ile	His	Arg	Ile	Leu	Pro
					405					410					415	
35	Pro	Asp	Ser	Gly	Val	Trp	Val	Cys	Ser	Val	Asn	Thr	Val	Ala	Gly	Met
				420					425					430		
	Val	Glu	Lys	Pro	Phe	Asn	Ile	Ser	Val	Lys	Val	Leu	Pro	Lys	Pro	Leu
			435					440				445				
40	Asn	Ala	Pro	Asn	Val	Ile	Asp	Thr	Gly	His	Asn	Phe	Ala	Val	Ile	Asn
		450					455					460				
	Ile	Ser	Ser	Glu	Pro	Tyr	Phe	Gly	Asp	Gly	Pro	Ile	Lys	Ser	Lys	Lys
	465					470					475					480
45	Leu	Leu	Tyr	Lys	Pro	Val	Asn	His	Tyr	Glu	Ala	Trp	Gln	His	Ile	Gln
					485					490					495	
	Val	Thr	Asn	Glu	Ile	Val	Thr	Leu	Asn	Tyr	Leu	Glu	Pro	Arg	Thr	Glu
				500					505					510		
50	Tyr	Glu	Leu	Cys	Val	Gln	Leu	Val	Arg	Arg	Gly	Glu	Gly	Gly	Glu	Gly
			515					520					525			
	His	Pro	Gly	Pro	Val	Arg	Arg	Phe	Thr	Thr	Ala	Ser	Ile	Gly	Leu	Pro
		530					535					540				
55	Pro	Pro	Arg	Gly	Leu	Asn	Leu	Leu	Pro	Lys	Ser	Gln	Thr	Thr	Leu	Asn
	545					550					555					560

EP 1 187 918 B9

	Leu	Thr	Trp	Gln	Pro	Ile	Phe	Pro	Ser	Ser	Glu	Asp	Asp	Phe	Tyr	Val
					565					570					575	
5	Glu	Val	Glu	Arg	Arg	Ser	Val	Gln	Lys	Ser	Asp	Gln	Gln	Asn	Ile	Lys
				580					585					590		
	Val	Pro	Gly	Asn	Leu	Thr	Ser	Val	Leu	Leu	Asn	Asn	Leu	His	Pro	Arg
			595					600					605			
10	Glu	Gln	Tyr	Val	Val	Arg	Ala	Arg	Val	Asn	Thr	Lys	Ala	Gln	Gly	Glu
		610					615					620				
	Trp	Ser	Glu	Asp	Leu	Thr	Ala	Trp	Thr	Leu	Ser	Asp	Ile	Leu	Pro	Pro
	625					630					635				640	
15	Gln	Pro	Glu	Asn	Ile	Lys	Ile	Ser	Asn	Ile	Thr	His	Ser	Ser	Ala	Val
				645						650					655	
	Ile	Ser	Trp	Thr	Ile	Leu	Asp	Gly	Tyr	Ser	Ile	Ser	Ser	Ile	Thr	Ile
				660					665					670		
20	Arg	Tyr	Lys	Val	Gln	Gly	Lys	Asn	Glu	Asp	Gln	His	Val	Asp	Val	Lys
			675					680					685			
	Ile	Lys	Asn	Ala	Thr	Ile	Ile	Gln	Tyr	Gln	Leu	Lys	Gly	Leu	Glu	Pro
		690					695					700				
25	Glu	Thr	Ala	Tyr	Gln	Val	Asp	Ile	Phe	Ala	Glu	Asn	Asn	Ile	Gly	Ser
	705				710						715				720	
	Ser	Asn	Pro	Ala	Phe	Ser	His	Glu	Leu	Val	Thr	Leu	Pro	Glu	Ser	Gln
				725						730				735		
30	Ala	Pro	Ala	Asp	Leu	Gly	Gly	Gly	Lys	Glu	Pro	Lys	Ser	Cys	Asp	Lys
			740					745						750		
	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro
			755				760						765			
35	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser
	770					775					780					
	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp
	785				790						795				800	
40	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn
				805					810						815	
	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val
			820						825					830		
45	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu
			835				840						845			
	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys
		850					855					860				
50	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr
	865				870						875				880	
	Leu	Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr
				885						890					895	
55	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu
			900						905					910		

EP 1 187 918 B9

	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu
			915					920					925			
5	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys
		930					935					940				
	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu
	945					950					955					960
10	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly
				965						970					975	

Lys

15

<210> 2
 <211> 704
 <212> PRT
 <213> Homo sapiens

20

<400> 2

25

30

35

40

45

50

55

EP 1 187 918 B9

	Met	Asp	Ser	Leu	Ala	Ser	Leu	Val	Leu	Cys	Gly	Val	Ser	Leu	Leu	Leu	
	1				5					10					15		
5	Ser	Gly	Thr	Val	Glu	Gly	Ala	Met	Asp	Leu	Ile	Leu	Ile	Asn	Ser	Leu	
				20					25					30			
	Pro	Leu	Val	Ser	Asp	Ala	Glu	Thr	Ser	Leu	Thr	Cys	Ile	Ala	Ser	Gly	
			35					40					45				
10	Trp	Arg	Pro	His	Glu	Pro	Ile	Thr	Ile	Gly	Arg	Asp	Phe	Glu	Ala	Leu	
		50					55					60					
	Met	Asn	Gln	His	Gln	Asp	Pro	Leu	Glu	Val	Thr	Gln	Asp	Val	Thr	Arg	
		65				70					75					80	
15	Glu	Trp	Ala	Lys	Lys	Val	Val	Trp	Lys	Arg	Glu	Lys	Ala	Ser	Lys	Ile	
					85					90					95		
	Asn	Gly	Ala	Tyr	Phe	Cys	Glu	Gly	Arg	Val	Arg	Gly	Glu	Ala	Ile	Arg	
				100					105					110			
20	Ile	Arg	Thr	Met	Lys	Met	Arg	Gln	Gln	Ala	Ser	Phe	Leu	Pro	Ala	Thr	
			115					120					125				
	Leu	Thr	Met	Thr	Val	Asp	Lys	Gly	Asp	Asn	Val	Asn	Ile	Ser	Phe	Lys	
		130					135					140					
25	Lys	Val	Leu	Ile	Lys	Glu	Glu	Asp	Ala	Val	Ile	Tyr	Lys	Asn	Gly	Ser	
		145				150					155				160		
	Phe	Ile	His	Ser	Val	Pro	Arg	His	Glu	Val	Pro	Asp	Ile	Leu	Glu	Val	
					165					170					175		
30	His	Leu	Pro	His	Ala	Gln	Pro	Gln	Asp	Ala	Gly	Val	Tyr	Ser	Ala	Arg	
				180					185					190			
	Tyr	Ile	Gly	Gly	Asn	Leu	Phe	Thr	Ser	Ala	Phe	Thr	Arg	Leu	Ile	Val	
			195					200					205				
35	Arg	Arg	Cys	Glu	Ala	Gln	Lys	Trp	Gly	Pro	Glu	Cys	Asn	His	Leu	Cys	
		210					215					220					
	Thr	Ala	Cys	Met	Asn	Asn	Gly	Val	Cys	His	Glu	Asp	Thr	Gly	Glu	Cys	
		225				230					235				240		

	Ile	Cys	Pro	Pro	Gly	Phe	Met	Gly	Arg	Thr	Cys	Glu	Lys	Ala	Cys	Glu	
					245					250						255	
5	Leu	His	Thr	Phe	Gly	Arg	Thr	Cys	Lys	Glu	Arg	Cys	Ser	Gly	Gln	Glu	
				260					265					270			
	Gly	Cys	Lys	Ser	Tyr	Val	Phe	Cys	Leu	Pro	Asp	Pro	Tyr	Gly	Cys	Ser	
			275					280					285				
10	Cys	Ala	Thr	Gly	Trp	Lys	Gly	Leu	Gln	Cys	Asn	Glu	Ala	Cys	His	Pro	
		290					295					300					
	Gly	Phe	Tyr	Gly	Pro	Asp	Cys	Lys	Leu	Arg	Cys	Ser	Cys	Asn	Asn	Gly	
	305					310				315						320	
15	Glu	Met	Cys	Asp	Arg	Phe	Gln	Gly	Cys	Leu	Cys	Ser	Pro	Gly	Trp	Gln	
				325					330						335		
	Gly	Leu	Gln	Cys	Glu	Arg	Glu	Gly	Ile	Pro	Arg	Met	Thr	Pro	Lys	Ile	
				340					345					350			
20	Val	Asp	Leu	Pro	Asp	His	Ile	Glu	Val	Asn	Ser	Gly	Lys	Phe	Asn	Pro	
			355					360					365				
	Ile	Cys	Lys	Ala	Ser	Gly	Trp	Pro	Leu	Pro	Thr	Asn	Glu	Glu	Met	Thr	
		370				375						380					
25	Leu	Val	Lys	Pro	Asp	Gly	Thr	Val	Leu	His	Pro	Lys	Asp	Phe	Asn	His	
	385					390					395					400	
	Thr	Asp	His	Phe	Ser	Val	Ala	Ile	Phe	Thr	Ile	His	Arg	Ile	Leu	Pro	
				405					410						415		
30	Pro	Asp	Ser	Gly	Val	Trp	Val	Cys	Ser	Val	Asn	Thr	Val	Ala	Gly	Met	
				420					425					430			
	Val	Glu	Lys	Pro	Phe	Asn	Ile	Ser	Val	Lys	Val	Leu	Pro	Lys	Pro	Leu	
			435					440					445				
35	Asn	Ala	Pro	Asn	Val	Ile	Asp	Thr	Gly	His	Asn	Phe	Ala	Val	Ile	Asn	
		450				455						460					
	Ile	Ser	Ser	Glu	Pro	Tyr	Phe	Gly	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	
	465					470				475						480	
40	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	
				485					490					495			
	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	
				500					505					510			
45	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	
			515				520						525				
	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	
		530				535				540							
50	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	
	545					550				555						560	
	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	
				565					570					575			
55	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	
			580				585						590				

Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
 595 600 605
 5 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys
 610 615 620
 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
 625 630 635 640
 10 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
 645 650 655
 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
 660 665 670
 15 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
 675 680 685
 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 690 695 700
 20

Claims

- 25
1. A polypeptide comprising the Tek extracellular domain shown as residues 19-745 of SEQ ID NO:1, wherein the polypeptide lacks residues 473-745 of SEQ ID NO: 1 containing fibronectin type III (FNIII) motifs and wherein the polypeptide has a higher binding affinity for angiopoietin-1 or angiopoietin-2 or angiopoietin-4 than does a polypeptide comprising the full length Tek extracellular domain.
 - 30 2. The polypeptide of claim 1, wherein the Tek extracellular domain is selected from the group consisting of:
 - (a) residues 23-472 of SEQ NO: 2;
 - (b) variants that are at least 95% identical to (a);
 - 35 (c) variants that are at least 98% identical to (a);
 - (d) variants that are at least 99% identical to (a); and
 - (e) residues 19-472 of SEQ ID NO:2.
 - 40 3. The polypeptide of claim 2, which consists of residues 19-704 or 23-704 of SEQ ID NO: 2
 4. A nucleic acid encoding a polypeptide according to claim 1, 2 or 3.
 5. The nucleic acid of claim 4, further encoding a signal peptide sequence.
 - 45 6. The nucleic acid of claim 5 that encodes SEQ ID NO: 2.
 7. A polypeptide produced by a process comprising expressing a nucleic acid according to one of claims 4, 5 or 6 in a recombinant host cell under conditions that permit expression of the polypeptide.
 - 50 8. The polypeptide of claim 7 wherein the process comprises expressing a nucleic acid according to claim 5 or claim 6 and further comprises collecting the polypeptide secreted from the host cell.
 9. A soluble Tek multimer comprising a plurality of polypeptides according to any one of claims 1, 2, 3, 7 or 8.
 - 55 10. The soluble Tek multimer of claim 9 wherein the multimer is a dimer or trimer.
 11. The soluble Tek multimer of claim 9 or claim 10, wherein the multimer comprises an Fc polypeptide, a leucine zipper, or a peptide linker.

12. The use of a polypeptide according to one of claims 1, 2, 3, 7 or 8 in the manufacture of a medicament for use in inhibiting angiogenesis in a mammal.
13. The use of a soluble Tek multimer as claimed in any one of claims 9-11 in the manufacture of a medicament for use in inhibiting angiogenesis in a mammal.
14. The use of claim 13 wherein the Tek is human Tek.
15. The use of any one of claims 12-14 wherein the medicament further comprises a pharmaceutically acceptable carrier.
16. The use of any one of claims 12-15 wherein the medicament is used in the treatment of a disease or condition mediated by angiogenesis.
17. The use of claim 16 wherein the disease or condition is **characterised by** ocular neovascularization.
18. The use of claim 16 wherein the disease or condition is a solid tumour.
19. The use of any one of claims 12-18 wherein the medicament further comprises a second chemotherapeutic agent.
20. The use of any one of claims 12-19 wherein the medicament is suitable for use in combination with radiation.
21. The use of claim 19 or claim 20, wherein the second chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, vinca alkaloids and other plant-derived chemotherapeutics, nitrosoureas, antitumour antibiotics, antitumour enzymes, topoisomerase inhibitors, platinum analogs, adrenocortical suppressants, hormones, hormone agonists, hormone antagonists, antibodies, immunotherapeutics, blood cell factors, radiotherapeutics, and biological response modifiers.
22. The use of claim 19 or claim 20, wherein the second chemotherapeutic agent is selected from the group consisting of cisplatin, cyclophosphamide, mechlorethamine, melphalan, bleomycin, carboplatin, fluorouracil, 5-fluorodeoxyuridine, methotrexate, taxol, asparaginase, vincristine, and vinblastine, lymphokines and cytokines such as interleukins, interferons (including alpha, beta, or delta), and TNF, chlorambucil, busuffan, carmustine, lomustine, semustine, streptozocin, dacarbazine, cytarabine, mercaptopurine, thioguanine, vindesine, etoposide, teniposide, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin, mitomycin, L-asparaginase, hydroxyurea, methylhydrazine, mitotane, tamoxifen, and fluoxymesterone.
23. The use of claim 19 or claim 20, wherein the second chemotherapeutic agent is selected from the group consisting of Flt3 ligand, CD40 ligand, interleukin-2, interleukin-12, 4-1BB ligand, anti-4-1BB antibodies, TNF antagonists and TNF receptor antagonists, TRAIL, CD 148 agonists, VEGF antagonists, and VEGF receptor antagonists.
24. The use of a Tek antagonist selected from the group consisting of: (a) a polypeptide according to one of claims 1, 2, 3, 7 or 8; and (b) a soluble Tek multimer according to one of claims 9-11; in the manufacture of a medicament for use inhibiting the binding of a Tek ligand to Tek in a mammal.
25. A method for determining whether an antibody that binds to a polypeptide of any one of claims 1, 2, 3, 7 or 8 is a Tek antagonist comprising determining whether the antibody is a Tek antagonist by its ability to inhibit the binding of Tek ligand to the polypeptide of residues 23-704 of SEQ ID NO:2.

Patentansprüche

1. Polypeptid das die Tek extrazelluläre Domäne, die als Reste 19 -745 der SEQ ID Nr. 1 gezeigt werden, aufweist, worin dem Polypeptid die Reste 473-745 der SEQ ID Nr. 1 fehlen die die Fibronectin Typ III (FNIII) Motive beinhalten und worin das Polypeptid eine höhere Bindungsaffinität für Angiopoietin-1 oder Angiopoietin-2 oder Angiopoietin-4 hat als Polypeptide die die Tek extrazelluläre Domäne in voller Länge aufweisen.
2. Polypeptid gemäß Anspruch 1, worin die Tek extrazelluläre Domäne aus einer Gruppe ausgewählt ist, die besteht aus:

- (a) den Resten 23 - 472 der SEQ ID Nr. 2;
- (b) Varianten die zumindest zu 95 % identisch sind zu (a);
- (c) Varianten die zumindest zu 98 % identisch sind zu (a);
- (d) Varianten die zumindest zu 99 % identisch sind zu (a); und
- (e) den Resten 19 - 472 der SEQ ID Nr. 2

3. Polypeptid nach Anspruch 2, welches aus den Resten 19 -704 oder 23 - 704 der SEQ ID Nr. 2 besteht.
4. Nukleinsäure die ein Polypeptid nach den Ansprüchen 1, 2 oder 3 kodiert.
5. Nukleinsäure nach Anspruch 4, die weiters eine Signalpeptidsequenz kodiert.
6. Nukleinsäure nach Anspruch 5, welche die SEQ ID Nr. 2 kodiert.
7. Polypeptid durch eine Verfahren hergestellt wird, welches das Exprimieren einer Nukleinsäure nach einem der Ansprüche 4, 5 oder 6 in einer rekombinanten Wirtszelle unter Bedingungen die die Expression des Polypeptids zulassen, aufweist.
8. Polypeptid nach Anspruch 7, worin das Verfahren das Exprimieren einer Nukleinsäure nach Anspruch 5 oder Anspruch 6 aufweist und weiters das Sammeln das von der Wirtszelle sekretierte Polypeptid aufweist.
9. Lösliches Tek-Multimer das eine Vielzahl an Polypeptiden gemäß einem der Ansprüche 1, 2, 3, 7 oder 8 aufweist.
10. Lösliches Tek-Multimer nach Anspruch 9, worin das Multimer ein Dimer oder ein Trimer ist
11. Lösliches Tek-Multimer nach Anspruch 9 oder Anspruch 10, worin das Multimer ein Fc Polypeptid, einen Leucine Zipper, oder einen Peptidlinker aufweist.
12. Verwendung eines Polypeptids gemäß einem der Ansprüche 1, 2, 3, 7 oder 8 bei der Herstellung eines Medikaments zur Verwendung in der Inhibierung der Angiogenese in einem Säugetier.
13. Die Verwendung eines löslichen Tek Multimers wie gemäß einem der Ansprüche 9-11 beansprucht bei der Herstellung eines Medikaments zur Verwendung in der Inhibierung der Angiogenese in einem Säugetier.
14. Verwendung gemäß Anspruch 13, worin Tek humanes Tek ist.
15. Verwendung gemäß einem der Ansprüche 12-14 worin das Medikament weiters einen pharmazeutisch akzeptablen Träger aufweist.
16. Verwendung gemäß einem der Ansprüche 12-15 worin das Medikament zur Behandlung einer Krankheit oder eines Zustandes die/der durch Angiogenese vermittelt wird.
17. Verwendung nach Anspruch 16 worin die Krankheit oder der Zustand durch okuläre Neovaskularisation **gekennzeichnet** ist.
18. Verwendung nach Anspruch 16 worin die Krankheit oder der Zustand ein solider Tumor ist.
19. Verwendung gemäß einem der Ansprüche 2 - 18 worin das Medikament weiters einen zweiten chemotherapeutischen Wirkstoff aufweist.
20. Verwendung gemäß einem der Ansprüche 12-19 worin das Medikament geeignet zur Verwendung in Kombination mit Strahlung ist.
21. Verwendung gemäß Anspruch 19 oder Anspruch 20, worin der zweite chemotherapeutische Wirkstoff aus der Gruppe ausgewählt wird, die aus Alkylanzien, Antimetaboliten, Vinca-Alkaloide und anderen von Pflanzen-abgeleiteten Chemotherapeutika, Nitrosoharnstoffe, Antitumor-Antibiotika, Antitumor-Enzyme, Topoisomerase Inhibitoren, Platin-Analoga, Adrenocorticales Suppressiva, Hormone, Hormonagonisten, Hormonantagonisten, Antikörper, Immuntherapeutika, Blutzellenfaktoren, Radiotherapeutika, und biologische Antwortmodifikatoren besteht.

22. Verwendung nach Anspruch 19 oder Anspruch 20, worin der zweite chemotherapeutische Wirkstoff aus der Gruppe ausgewählt wird, die aus Cisplatin, Cyclophosphamid, Mechlorethamin, Melphalan, Bleomycin, Carboplatin, Fluoruracil, 5-Fluordeoxyuridin, Methotrexat, Taxol, Asparaginase, Vincristin, und Vinblastin. Lymphokine und Cytokine wie z. B. Interleukine, Interferone (einschließlich alpha, beta, oder delta), und TNF, Chlorambucil, Busulfan, Carmustin, Lomustin, Semustin, Streptozocin, Dacarbazin, Cytarabin, Mercaptopurin, Thioguanin, Vindesin, Etoposid, Teniposid, Dactinomycin, Daunorubicin, Doxorubicin, Bleomycin, Plicamycin, Mitomycin, L-Asparaginase, Hydroxyharnstoff, Methylhydrazine, Mitotan, Tamoxifen und Fluoxymesteron besteht.
23. Verwendung nach Anspruch 19 oder Anspruch 20, worin der zweite chemotherapeutische Wirkstoff aus der Gruppe ausgewählt wird, die aus Flt3 Ligand, CD40 Ligand, Interleukin-2, Interleukin-12, 4-1BB Ligand, Anti-4-1BB Antikörper, TNF Antagonisten und TNF Rezeptor Antagonisten, TRAIL, CD148 Agonisten, VEGF Antagonisten, und VEGF Rezeptor Antagonisten besteht.
24. Verwendung eines Tek Antagonisten der aus der Gruppe ausgewählt die aus: (a) einem Polypeptid gemäß einem der Ansprüche 1, 2, 3, 7 oder 8, und (b) einem löslichen Tek Multimer gemäß einem der Ansprüche 9 - 1-1 besteht; bei der Herstellung eines Medikaments zur Inhibierung der Bindung eines Tek Liganden an Tek in einem Säugetier.
25. Verfahren zur Bestimmung ob ein Antikörper, der an ein Polypeptid gemäß einem der Ansprüche 1, 2, 3, 7 oder 8 bindet ein Tek-Antagonist ist, welches Verfahren das Bestimmen enthält ob der Antikörper ein Tek Antagonist durch seine Fähigkeit, die Bindung des Tek-Liganden an das Polypeptid der Reste 23-704 der SEQ ID Nr. 2 zu inhibieren, ist.

Revendications

1. Polypeptide comprenant le domaine extracellulaire Tek représenté sous la forme des résidus 19-745 de la SEQ ID NO :1, dans laquelle le polypeptide ne présente pas les résidus 473-745 de la SEQ ID NO :1 comprenant les motifs de la fibronectine de type III (FNIII) et dans lequel le polypeptide présente une affinité de liaison à l'angiopoïétine-1, l'angiopoïétine-2 ou l'angiopoïétine-4 supérieure à celle d'un polypeptide comprenant le domaine extracellulaire Tek dans toute sa longueur.
2. Polypeptide selon la revendication 1, dans lequel le domaine extracellulaire Tek est choisi parmi le groupe constitué :
- (a) des résidus 23-472 de la SEQ ID NO :2 ;
 - (b) de variants identiques à au moins 95% par rapport à (a);
 - (c) de variants identiques à au moins 98% par rapport à (a) ;
 - (d) de variants identiques à au moins 99% par rapport à (a) ; et
 - (e) des résidus 19-472 de la SEQ ID NO :2.
3. Polypeptide selon la revendication 2, qui est constitué des résidus 19-704 ou 23-704 de la SEQ ID NO :2.
4. Acide nucléique codant pour un polypeptide selon la revendication 1, 2 ou 3.
5. Acide nucléique selon la revendication 4 codant en outre pour une séquence de peptide signal.
6. Acide nucléique selon la revendication 5 qui code pour la SEQ ID NO :2.
7. Polypeptide produit par un procédé comprenant l'expression d'un acide nucléique selon l'une des revendications 4, 5 ou 6 dans une cellule hôte recombinante dans des conditions qui permettent l'expression du polypeptide.
8. Polypeptide selon la revendication 7, dans lequel le procédé comprend l'expression d'un acide nucléique selon la revendication 5 ou la revendication 6 et comprend en outre la récupération du polypeptide sécrété par la cellule hôte.
9. Multimère Tek soluble comprenant une pluralité de polypeptides selon l'une quelconque des revendications 1, 2, 3, 7 ou 8.
10. Multimère Tek soluble selon la revendication 9, dans laquelle le multimère est un dimère ou un trimère.
11. Multimère Tek soluble selon la revendication 9 ou la revendication 10, dans laquelle le multimère comprend un

polypeptide Fc, un domaine glissière de leucine ou un lieu de peptide.

12. Utilisation d'un polypeptide selon l'une quelconque des revendications 1, 2, 3, 7 ou 8 dans la préparation d'un médicament destiné à être utilisé dans l'inhibition de l'angiogenèse chez un mammifère.

13. Utilisation d'un multimère Tek soluble selon l'une quelconque des revendications 9 à 11 dans la préparation d'un médicament destiné à être utilisé dans l'inhibition de l'angiogenèse chez un mammifère.

14. Utilisation selon la revendication 13 dans laquelle le Tek est un Tek humain.

15. Utilisation selon l'une quelconque des revendications 12 à 14 dans laquelle le médicament comprend en outre un excipient pharmaceutiquement acceptable.

16. Utilisation selon l'une quelconque des revendications 12 à 15 dans laquelle le médicament est utilisé dans le traitement d'une maladie ou d'un état pathologique médié par l'angiogenèse.

17. Utilisation selon la revendication 16 dans laquelle la maladie ou l'état pathologique est **caractérisé par** une néo-vascularisation oculaire.

18. Utilisation selon la revendication 16 dans laquelle la maladie ou l'état pathologique est une tumeur solide.

19. Utilisation selon l'une quelconque des revendications 12 à 18 dans laquelle le médicament comprend en outre un deuxième agent chimiothérapique.

20. Utilisation selon l'une quelconque des revendications 12 à 19 dans laquelle le médicament est apte à être utilisé en combinaison avec un rayonnement.

21. Utilisation selon la revendication 19 ou la revendication 20, dans laquelle le deuxième agent chimiothérapique est choisi dans le groupe constitué des agents d'alkylation, antimétabolites, vinca-alcaloïdes et autres agents chimiothérapiques dérivés de végétaux, nitroso-urées, antibiotiques antitumoraux, enzymes antitumorales, inhibiteurs de topoisomérase, analogues de platine, agents supprimeurs corticosurrénaux, hormones, agonistes hormonaux, antagonistes hormonaux, anticorps, agents immunothérapeutiques, facteurs de cellules sanguines, agents radiothérapeutiques et modificateurs de réponse biologique.

22. Utilisation selon la revendication 19 ou la revendication 20, dans laquelle le deuxième agent chimiothérapique est choisi dans le groupe constitué de cisplatine, cyclophosphamide, méchlorétamine, melphalane, béomycine, carbo-platine, fluorouracile, 5-fluorodésoxyuridine, méthotrexate, taxol, asparaginase, vincristine et vinblastine, lymphokines et cytokines comme les interleukines, interférons (notamment alpha, bêta ou delta) et TNF, chlorambucile, busulfane, carmustine, lomustine, semustine, streptozocine, dacarbazine, cytarabine, mercaptopurine, thioguanine, vindésine, étoposide, téniposide, dactinomycine, daunorubicine, doxorubicine, bléomycine, plicamycine, mitomycine, L-asparaginase, hydroxyurée, méthylhydrazine, mitotane, tamoxifène et fluoxymestérone.

23. Utilisation selon la revendication 19 ou la revendication 20, dans laquelle le deuxième agent chimiothérapique est choisi dans le groupe constitué des ligand Flt3, ligand CD40, interleukine-2, interleukine-12, ligand 4-1BB, anticorps anti-4-1BB, antagonistes TNF et antagonistes du récepteur TNF, TRAIL, agonistes CD 148, antagonistes VEGF et antagonistes du récepteur VEGF.

24. Utilisation d'un antagoniste Tek choisi dans le groupe constitué de : (a) un polypeptide selon l'une des revendications 1, 2, 3, 7 ou 8 ; et (b) un multimère Tek soluble selon l'une des revendications 9 à 11 ; dans la préparation d'un médicament destiné à être utilisé dans l'inhibition de la liaison d'un ligand Tek au Tek chez un mammifère.

25. Procédé destiné à déterminer si un anticorps qui lie un polypeptide selon l'une quelconque des revendications 1, 2, 3, 7 ou 8 est un antagoniste Tek consistant à déterminer si l'anticorps est un antagoniste Tek par son aptitude à inhiber la liaison du ligand Tek au polypeptide des résidus 23-704 de la SEQ ID NO :2.




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 5447860 A [0007] [0022] [0109]
- US 6057435 A [0007]
- WO 9818914 A [0009] [0009]
- US 5674704 A [0023]
- US 5716805 A [0026]
- US 5554512 A [0030]
- US 5763223 A [0041]
- WO 9310151 A [0050] [0050]
- US 5457035 A [0050]
- US 4751180 A [0052]
- US 4935233 A [0052]
- US 5073627 A [0052]
- WO 9410308 A [0053]
- EP 36776 A [0069]
- EP 73657 A, Hitzeman [0070]
- US 4965195 A [0080]
- EP 367566 A [0080]
- US 4968607 A [0080]
- EP 460846 A [0080]
- US 5843705 A [0082]
- US 5880327 A [0082]
- US 5639947 A [0082]
- US 5889189 A [0082]
- US 5814318 A [0090]
- US 5569825 A [0090]
- US 5545806 A [0090]
- WO 0018437 A, Holmes [0132]

Non-patent literature cited in the description

- FOLKMAN. *N. Engl. J. Med.*, 1971, vol. 285, 1182 [0004]
- FOLKMAN et al. *Nature*, 1989, vol. 339, 58 [0004]
- KIM et al. *Nature*, 1993, vol. 362, 841 [0004]
- HORI et al. *Cancer Res.*, 1991, vol. 51, 6180 [0004]
- BERGERS et al. *Science*, 1999, vol. 284, 808 [0004]
- DAVIS et al. *Cell*, 1996, vol. 87, 1161 [0007] [0139]
- MAISONPIERRE et al. *Science*, 1997, vol. 277, 55 [0007] [0139] [0139]
- VALENZUELA et al. *Proc. Natl. Acad. Sci. USA*, 1999, vol. 96, 1904 [0007]
- *J. Clin. Invest.*, 1997, vol. 199 (8), 2072 [0009]
- *Proc. Natl. Acad. Sci. USA*, 1998, vol. 95, 8829 [0009]
- ASHKENAZI et al. *Proc. Natl. Acad. Sci. USA*, 1991, vol. 88, 10535 [0048]
- BYRN et al. *Nature*, 1990, vol. 344, 677 [0048]
- HOLLENBAUGH ; ARUFFO. Construction of Immunoglobulin Fusion Proteins. *Current Protocols in Immunology*, 1992, vol. 4, 10.19.1-10.19.11 [0048]
- BAUM et al. *EMBO J.*, 1994, vol. 13, 3992 [0050]
- LANDSCHULZ et al. *Science*, 1988, vol. 240, 1759 [0053]
- HOPPE et al. *FEBS Lett.*, 1994, vol. 344, 191 [0053]
- FANSLOW et al. *Semin. Immunol.*, 1994, vol. 6, 267 [0053]
- VAN DER GEER et al. *Ann. Rev. Cell Biol.*, 1994, vol. 10, 251 [0054]
- NEEDLEMAN ; WUNSCH. *J. Mol. Biol.*, 1970, vol. 48, 443 [0058]
- SMITH ; WATERMAN. *Adv. Appl. Math.*, 1981, vol. 2, 482 [0058]
- DEVEREUX et al. *Nucl. Acids Res.*, 1984, vol. 12, 387 [0058]
- GRIBSKOV ; BURGESS. *Nucl. Acids Res.*, 1986, vol. 14, 6745 [0058]
- SCHWARTZ ; DAYHOFF. *Atlas of Protein Sequence and Structure*, 1979, 353-358 [0058]
- SAMBROOK. *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, 1989 [0064]
- MANIATIS. *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, 1982 [0064]
- AUSUBEL. *Current Protocols in Molecular Biology*, Wiley and Sons, 1989 [0064]
- POUWELS et al. *Cloning Vectors: A Laboratory Manual*, 1985 [0066]
- CHANG et al. *Nature*, 1978, vol. 275, 615 [0069]
- GOEDDEL et al. *Nature*, 1979, vol. 281, 544 [0069]
- GOEDDEL et al. *Nucl. Acids Res.*, 1980, vol. 8, 4057 [0069]
- MANIATIS. *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1982, 412 [0069]
- HITZEMAN et al. *J. Biol. Chem.*, 1980, vol. 255, 2073 [0070]
- HESS et al. *J. Adv. Enzyme Reg.*, 1968, vol. 7, 149 [0070]
- HOLLAND et al. *Biochem.*, 1978, vol. 17, 4900 [0070]

- **RUSSELL et al.** *J. Biol. Chem.*, 1982, vol. 258, 2674 [0070]
- **BEIER et al.** *Nature*, 1982, vol. 300, 724 [0070]
- **KURJAN et al.** *Cell*, 1982, vol. 30, 933 [0071]
- **BITTER et al.** *Proc. Natl. Acad. Sci. USA*, 1984, vol. 81, 5330 [0071]
- **HINNEN et al.** *Proc. Natl. Acad. Sci. USA*, 1978, vol. 75, 1929 [0072]
- **LUCKOW AND SUMMERS.** *Bio/Technology*, 1988, vol. 6, 47 [0074]
- **GLUZMAN et al.** *Cell*, 1981, vol. 23, 175 [0075]
- **MCMAHAN et al.** *EMBO J.*, 1991, vol. 10, 2821 [0075]
- **KAUFMAN ; RJ.** *Large Scale Mammalian Cell Culture*, 1990, 15-69 [0076]
- **FEIGNER et al.** *Proc. Natl. Acad. Sci. USA*, 1987, vol. 84, 7413 [0076]
- **SAMBROOK et al.** *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, 1989, vol. 1-3 [0076]
- **KAUFMAN et al.** *Meth. in Enzymology*, 1990, vol. 185, 487 [0076]
- **URLAUB ; CHASIN.** *Proc. Natl. Acad. Sci. USA*, 1980, vol. 77, 4216 [0076]
- **FIERS et al.** *Nature*, 1978, vol. 273, 113 [0077]
- **KAUFMAN.** *Meth. in Enzymology*, 1990 [0077]
- **MORRIS et al.** *Animal Cell Technology*, 1997, 529-534 [0078] [0078]
- **GINGERAS et al.** *J. Biol. Chem.*, 1982, vol. 257, 13475 [0078]
- **OH ; SARNOW.** *Current Opinion in Genetics and Development*, 1993, vol. 3, 295 [0078]
- **RAMESH et al.** *Nucleic Acids Research*, 1996, vol. 24, 2697 [0078]
- **MOSSER et al.** *Biotechniques*, 1997, vol. 22, 150 [0078]
- **MOSLEY et al.** *Cell*, 1989, vol. 59, 335 [0079]
- **OKAYAMA ; BERG.** *Mol. Cell. Biol.*, 1983, vol. 3, 280 [0079]
- **COSMAN et al.** *Mol. Immunol*, 1986, vol. 23, 935 [0079]
- **COSMAN et al.** *Nature*, 1984, vol. 312, 768 [0079]
- **Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses**, Plenum Press, 1980 [0086]
- **Antibodies: A Laboratory Manual**, Cold Spring Harbor Laboratory Press, 1988 [0086]
- **RIECHMANN et al.** *Nature*, 1988, vol. 332, 323 [0088]
- **LIU et al.** *PNAS*, 1987, vol. 84, 3439 [0088]
- **LARRICK et al.** *Bio/technology*, 1989, vol. 7, 934 [0088]
- **WINTER ; HARRIS.** *TIPS*, May 1993, vol. 14, 139 [0088]
- **TAKAHASHI et al.** *J. Am. Soc. Nephrol.*, 1999, vol. 10, 2135-45 [0105]
- **BROWDER ; KLEMENT et al.** *Cancer Research*, 2000, vol. 60, 1878 [0106]
- *J. Clin. Invest.*, 2000, vol. 105 (8), R15 [0106]
- **BARINAGA.** *Science*, 2000, vol. 288, 245 [0106]
- **MARTIN et al.** *In Vitro Cell Dev Biol*, 1997, vol. 33, 261 [0115]
- **KENYON et al.** *Invest Ophthalmol. & Visual Science*, 1996, vol. 37, 1625 [0117]
- **LYNCH ; MILLER.** *Eur. J. Immunol*, 1991, vol. 21, 1403 [0126]
- **BORGES et al.** *J. Immunol.*, 1999, vol. 163, 1289 [0126]